var title_f13_10_13472="MRI of ICA dissection";
var content_f13_10_13472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of ICA dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T1-weighted MRI showing a right internal carotid artery dissection as a crescent-shaped hypersignal within the internal carotid artery wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13472=[""].join("\n");
var outline_f13_10_13472=null;
var title_f13_10_13473="Patient information: Panic disorder (The Basics)";
var content_f13_10_13473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/32/32257\">",
"         Patient information: Generalized anxiety disorder (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Panic disorder (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/panic-disorder-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8300424\">",
"      <span class=\"h1\">",
"       What is panic disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Panic disorder is a condition that can make a person feel very scared and anxious for short periods of time. When this happens, it is called a &ldquo;panic attack.&rdquo; The attacks can also cause chest pain and breathing problems that cause people to visit doctors or emergency rooms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8300439\">",
"      <span class=\"h1\">",
"       What are the symptoms of panic disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with panic disorder have panic attacks that can make them:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Feel very scared and nervous",
"       </li>",
"       <li>",
"        Have physical symptoms such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        A fast heartbeat",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Stomachache",
"       </li>",
"       <li>",
"        Dizziness",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The attacks happen without warning and can last several minutes to an hour.",
"     </p>",
"     <p>",
"      People with panic disorder also:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Worry about having panic attacks in the future",
"       </li>",
"       <li>",
"        Avoid situations that might cause them to have a panic attack",
"       </li>",
"       <li>",
"        Often see doctors or go to emergency rooms when they have panic attacks",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8300454\">",
"      <span class=\"h1\">",
"       Is there a test for panic disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8300469\">",
"      <span class=\"h1\">",
"       How is panic disorder treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cognitive behavioral therapy (CBT) - In this type of therapy, you talk with a psychologist or counselor about the things you think and do. Then he or she helps you change how you think about your situation and how you react to it. This teaches you how to cope better with your panic disorder.",
"       </li>",
"       <li>",
"        Medicines &ndash; Some medicines used to treat depression or anxiety can help people with panic disorder. Your doctor or nurse will decide which medicines are best for your situation.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people have CBT and also take medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8300484\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you take medicines to treat panic disorder, talk to your doctor before you start trying to get pregnant. Some of the medicines used to treat panic disorder can cause problems for unborn babies, so you might need to switch medicines before you get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8300499\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=see_link\">",
"       Patient information: Generalized anxiety disorder (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/10/13473?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 84003 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13473=[""].join("\n");
var outline_f13_10_13473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8300424\">",
"      What is panic disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8300439\">",
"      What are the symptoms of panic disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8300454\">",
"      Is there a test for panic disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8300469\">",
"      How is panic disorder treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8300484\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8300499\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=related_link\">",
"      Patient information: Generalized anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_10_13474="What to do after a tick bite to prevent Lyme disease";
var content_f13_10_13474=[" <h1 id=\"patTopicTitle\">",
"  Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/10/13474/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13474/contributors\" id=\"au2858\">",
"       Linden Hu, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/10/13474/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13474/contributors\" id=\"se1447\">",
"       Allen C Steere, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/10/13474/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13474/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/10/13474?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TICK BITE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     There are many different types of ticks in the United States, some of which are capable of transmitting infections. The risk of developing these infections depends upon the geographic location, season of the year, type of tick, and, for Lyme disease, how long the tick was attached to the skin.",
"    </p>",
"    <p>",
"     While many people are concerned after being bitten by a tick, the risk of acquiring a tick-borne infection is quite low, even if the tick has been attached, fed, and is actually carrying an infectious agent. Ticks transmit infection only after they have attached and then taken a blood meal from their new host [",
"     <a class=\"abstract\" href=\"UTD.htm?13/10/13474/abstract/1\">",
"      1",
"     </a>",
"     ]. A tick that has not attached (and therefore has not yet become engorged from its blood meal) has not passed any infection. Since the deer tick that transmits Lyme disease must feed for &gt;36 hours before transmission of the spirochete, the risk of acquiring Lyme disease from an observed tick bite, for example, is only 1.2 to 1.4 percent, even in an area where the disease is common.",
"    </p>",
"    <p>",
"     If a person is bitten by a deer tick (the type of tick that carries Lyme disease), a healthcare provider will likely advise one of two approaches:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Observe and treat if signs or symptoms of infection develop",
"      </li>",
"      <li>",
"       Treat with a preventive antibiotic immediately",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There is no benefit of blood testing for Lyme disease at the time of the tick bite; even people who become infected will not have a positive blood test until approximately two to six weeks after the infection develops (post-tick bite).",
"    </p>",
"    <p>",
"     The history of the tick bite will largely determine which of these options is chosen. Before seeking medical attention, the affected person or household member should carefully remove the tick and make note of its appearance (",
"     <a class=\"graphic graphic_picture graphicRef51825 \" href=\"UTD.htm?15/16/15617\">",
"      picture 1",
"     </a>",
"     ). Only the Ixodes species of tick, also known as the deer tick, causes Lyme disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW TO REMOVE A TICK",
"     </span>",
"    </p>",
"    <p>",
"     The proper way to remove a tick is to use a set of fine tweezers and grip the tick as close to the skin as is possible. Do not use a smoldering match or cigarette, nail polish, petroleum jelly (eg, Vaseline), liquid soap, or kerosene because they may irritate the tick and cause it to behave like a syringe, injecting bodily fluids into the wound.",
"    </p>",
"    <p>",
"     The proper technique for tick removal includes the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Use fine tweezers to grasp the tick as close to the skin surface as possible.",
"      </li>",
"      <li>",
"       Pull backwards gently but firmly, using an even, steady pressure. Do not jerk or twist.",
"      </li>",
"      <li>",
"       Do not squeeze, crush, or puncture the body of the tick, since its bodily fluids may contain infection-causing organisms.",
"      </li>",
"      <li>",
"       After removing the tick, wash the skin and hands thoroughly with soap and water.",
"      </li>",
"      <li>",
"       If any mouth parts of the tick remain in the skin, these should be left alone; they will be expelled on their own. Attempts to remove these parts may result in significant skin trauma.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      AFTER THE TICK IS REMOVED",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Tick characteristics",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is helpful if the person can provide information about the size of the tick, whether it was actually attached to the skin, if it was engorged (that is, full of blood), and how long it was attached [",
"     <a class=\"abstract\" href=\"UTD.htm?13/10/13474/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The size and color of the tick help to determine what kind of tick it was (",
"       <a class=\"graphic graphic_picture graphicRef51825 \" href=\"UTD.htm?15/16/15617\">",
"        picture 1",
"       </a>",
"       and",
"       <a class=\"graphic graphic_figure graphicRef68309 \" href=\"UTD.htm?39/6/40037\">",
"        figure 1",
"       </a>",
"       );",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Ticks that are brown and approximately the size of a poppy seed or pencil point are deer ticks. These can transmit Borrelia burgdorferi (the bacterium that causes Lyme disease) and a number of other tick-borne infections, including babesiosis and anaplasmosis. Deer ticks live primarily in the northeast and mid-Atlantic region (Maine to Virginia) and in the midwest (Minnesota and Wisconsin) region of the United States, and less commonly in the western US (northern California).",
"      </li>",
"      <li>",
"       Ticks that are brown with a white collar and about the size of a pencil eraser are more likely to be dog ticks (Dermacentor species). These ticks do not carry Lyme disease, but can rarely carry another tick-borne infection called Rocky Mountain spotted fever that can be serious or even fatal.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A brown to black tick with a white splotch on its back is likely a female Amblyomma americanum (Lone Star tick; named after the white splotch) (",
"       <a class=\"graphic graphic_picture graphicRef50244 \" href=\"UTD.htm?23/3/23614\">",
"        picture 2",
"       </a>",
"       ). This species of tick has been reported to spread an illness called STARI (southern tick-associated rash illness). STARI causes a rash that is similar to the erythema migrans rash, but without the other features of Lyme disease. Although this rash is thought to be caused by an infection, a cause for the infection has not yet been identified. This type of tick can also carry and transmit another infection called human monocytic ehrlichiosis.",
"      </li>",
"      <li>",
"       A tick that was not attached, was easy to remove or just walking on the skin, and was still flat and tiny and not full of blood when it was removed could not have transmitted Lyme disease or any other infection since it had not yet taken a blood meal.",
"       <br/>",
"       <br/>",
"       Only ticks that are attached and have finished feeding or are near the end of their meal can transmit Lyme disease. After arriving on the skin, the tick that spreads Lyme disease usually takes 24 hours before feeding begins.",
"      </li>",
"      <li>",
"       Even if a tick is attached, it must have taken a blood meal to transmit Lyme disease. At least 36 to 48 hours of feeding is required for a tick to have fed and then transmit the bacterium that causes Lyme disease. After this amount of time, the tick will be engorged (full of blood). An engorged tick has a globular shape and is larger than an unengorged one.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The organism that causes Lyme disease, B. burgdorferi, lies dormant in the inner aspect of the tick's midgut. The organism becomes active only after exposure to the warm blood meal entering the tick's gut. Once active, the organism enters the tick's salivary glands. As the tick feeds, it must get rid of excess water through the salivary glands. Thus, the tick will literally salivate organisms into the wound, thereby passing the infection to the host.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Need for treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The clinician will review the description of the tick, along with any physical symptoms, to decide upon a course of action. The Infectious Diseases Society of America (IDSA) recommends preventive treatment with antibiotics only in people who meet",
"     <strong>",
"      ALL",
"     </strong>",
"     of the following criteria [",
"     <a class=\"abstract\" href=\"UTD.htm?13/10/13474/abstract/3\">",
"      3",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Attached tick identified as an adult or nymphal I. scapularis (deer) tick",
"      </li>",
"      <li>",
"       Tick is estimated to have been attached for &ge;36 hours (based upon how engorged the tick appears or the amount of time since outdoor exposure)",
"      </li>",
"      <li>",
"       Antibiotic treatment can begin within 72 hours of tick removal",
"      </li>",
"      <li>",
"       The local rate of tick infection with B. burgdorferi is &ge;20 percent (known to occur in parts of New England, parts of the mid-Atlantic states, and parts of Minnesota and Wisconsin)",
"      </li>",
"      <li>",
"       The person can take doxycycline (eg, the person is not pregnant or breastfeeding or a child &lt;8 years of age)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If the person meets ALL of the above criteria, the recommended dose of doxycycline is a single dose of 200 mg for adults and 4",
"     <span class=\"nowrap\">",
"      mg/kg,",
"     </span>",
"     up to a maximum dose of 200 mg, in children &ge; 8 years.",
"    </p>",
"    <p>",
"     If the person cannot take doxycycline, the IDSA does not recommend preventive treatment with an alternate antibiotic for several reasons: there are no data to support a short course of another antibiotic, a longer course of antibiotics may have side effects, antibiotic treatment is highly effective if Lyme disease were to develop, and the risk of developing a serious complication of Lyme disease after a recognized bite is extremely low.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      MONITORING FOR LYME DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     Many people have incorrect information about Lyme disease. For example, some people are concerned that Lyme disease is untreatable if antibiotics are not given early (this is untrue; even later features of Lyme disease can be effectively treated with appropriate antibiotics). Many local Lyme disease networks and national organizations disseminate unproven information and should not be the sole source of education about Lyme disease. Reputable sources are listed below (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Where to get more information'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Signs of Lyme disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Whether or not a clinician is consulted after a tick bite, the person who was bitten (or the parents, if a child was bitten) should observe the area of the bite for expanding redness, which would suggest erythema migrans (EM), the characteristic rash of Lyme disease (",
"     <a class=\"graphic graphic_picture graphicRef58798 \" href=\"UTD.htm?10/29/10704\">",
"      picture 3",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"      \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The EM rash is usually a salmon color although, rarely, it can be an intense red, sometimes resembling a skin infection. The color may be almost uniform. The lesion typically expands over a few days or weeks and can reach over 20 cm (8 inches) in diameter. As the rash expands, it can become clear (skin-colored) in the center. The center of the rash can then appear a lighter color than its edges or the rash can develop into a series of concentric rings giving it a \"bull's eye\" appearance. The rash usually causes no symptoms, although burning or itching has been reported.",
"    </p>",
"    <p>",
"     In people with early localized Lyme disease, EM occurs within one month of the tick bite, typically within a week of the tick bite, although only one-third of people recall the tick bite that gave them Lyme disease. Components of tick saliva can cause a short-lived (24 to 48 hours) rash that should not be confused with EM. This reaction usually does not expand to a size larger than a dime.",
"    </p>",
"    <p>",
"     Approximately 80 percent of people with Lyme disease develop EM; 10 to 20 percent of people have multiple lesions. If EM or other signs or symptoms suggestive of Lyme disease develop (",
"     <a class=\"graphic graphic_table graphicRef72018 \" href=\"UTD.htm?39/7/40060\">",
"      table 1",
"     </a>",
"     ), the person should see a healthcare provider for proper diagnosis and treatment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"      \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H81\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569823\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/2/22562?source=see_link\">",
"      Patient information: Rocky Mountain spotted fever (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11569857\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link\">",
"      Insect bites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"      Lyme carditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"      Prevention of Lyme disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"      Treatment of Lyme disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/lymedisease.html\">",
"      www.nlm.nih.gov/medlineplus/lymedisease.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/lymeDisease/\">",
"      www3.niaid.nih.gov/topics/lymeDisease/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Center for Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Division of Vector-Borne Infectious Diseases",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncidod/dvbid/lyme/\">",
"      www.cdc.gov/ncidod/dvbid/lyme/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lyme Disease Foundation, Inc.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aldf.com/faq.shtml\">",
"      www.aldf.com/faq.shtml",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/10/13474?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13474/abstract/1\">",
"      Steere AC. Lyme disease. N Engl J Med 2001; 345:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13474/abstract/2\">",
"      Sood SK, Salzman MB, Johnson BJ, et al. Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic. J Infect Dis 1997; 175:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13474/abstract/3\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_10_13474=[""].join("\n");
var outline_f13_10_13474=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TICK BITE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW TO REMOVE A TICK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           AFTER THE TICK IS REMOVED",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           MONITORING FOR LYME DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/6/40037\" title=\"figure 1\">",
"           Tick sizes and appearances",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/16/15617\" title=\"picture 1\">",
"           Tick comparison PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/3/23614\" title=\"picture 2\">",
"           Lone star tick PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/29/10704\" title=\"picture 3\">",
"           Erythema migrans PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?39/7/40060\" title=\"table 1\">",
"           Signs of Lyme disease",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_10_13475="Patient information: Seasonal allergies in children (The Basics)";
var content_f13_10_13475=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87053\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/59/23477\">",
"         Common causes of seasonal allergies",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24576\">",
"          Child with allergies",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?20/23/20860\">",
"           Causes and symptoms of common allergies",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/5/42066\">",
"         Patient information: Allergy shots (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/24/42370\">",
"         Patient information: Allergy skin testing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/58/17315\">",
"         Patient information: Asthma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/18/16674\">",
"         Patient information: Rinsing out your nose with salt water (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/38/37474\">",
"         Patient information: Seasonal allergies in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/27/5553\">",
"         Patient information: Allergic conjunctivitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/8/41092\">",
"         Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/40/5764\">",
"         Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Seasonal allergies in children (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H269187072\">",
"      <span class=\"h1\">",
"       What are seasonal allergies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Seasonal allergies, also called &ldquo;hay fever,&rdquo; are a group of conditions that can cause sneezing, a stuffy nose, or a runny nose. Symptoms occur only at certain times of the year. Most seasonal allergies are caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pollens from trees, grasses, or weeds (",
"        <a class=\"graphic graphic_figure graphicRef77269 \" href=\"UTD.htm?22/59/23477\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Mold spores, which grow when the weather is humid, wet, or damp",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Normally, people breathe in these substances without a problem. When a person has a seasonal allergy, his or her immune system acts as if the substance is harmful to the body. This causes symptoms.",
"     </p>",
"     <p>",
"      Many people first get seasonal allergies when they are children. Seasonal allergies are life-long, but symptoms can get better or worse over time. Seasonal allergies sometimes run in families.",
"     </p>",
"     <p>",
"      Some people have symptoms like those of seasonal allergies, but their symptoms last all year. Year-round symptoms are usually caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Insects, such as dust mites and cockroaches",
"       </li>",
"       <li>",
"        Animals, such as cats and dogs",
"       </li>",
"       <li>",
"        Mold spores",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Many children with seasonal allergies also have asthma. (Asthma is a condition that can make it hard to breathe.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H269187110\">",
"      <span class=\"h1\">",
"       What are the symptoms of seasonal allergies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of seasonal allergies can include (",
"      <a class=\"graphic graphic_table graphicRef86626 \" href=\"UTD.htm?20/23/20860\">",
"       table 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stuffy nose, runny nose, or sneezing a lot",
"       </li>",
"       <li>",
"        Itchy or red eyes",
"       </li>",
"       <li>",
"        Sore throat, or itchy throat or ears",
"       </li>",
"       <li>",
"        Waking up at night or trouble sleeping, which can lead to feeling tired or having trouble concentrating during the day",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Young children often do not blow their nose but instead sniff, cough, or clear their throat a lot. They might also get into the habit of breathing through their mouth because their nose is stuffy.",
"     </p>",
"     <p>",
"      Because children do not always understand what allergies are or how they affect people, they sometimes put up with severe symptoms. This can really affect their lives. Children with allergies can have trouble concentrating or doing school work. They can even have trouble with sports. Your child might not be able to tell you what is wrong, but you can look for symptoms that show up at the same time each year or last a long time. You might also be able to tell that a child has allergies by the way he or she looks (",
"      <a class=\"graphic graphic_picture graphicRef87001 \" href=\"UTD.htm?24/0/24576\">",
"       picture 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Seasonal allergy symptoms usually don&rsquo;t show up in children until after age 2. If your child is younger than 2 and has these symptoms, talk to his or her doctor about what might be causing them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H269187159\">",
"      <span class=\"h1\">",
"       Is there a test for seasonal allergies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your child&rsquo;s doctor will ask about his or her symptoms and do an exam. He or she might order other tests, such as a skin test. A skin test can help figure out what your child is allergic to. During a skin test, a doctor will put a drop of the substance your child might be allergic to on his or her skin, and make a tiny prick in the skin. Then, he or she will watch your child&rsquo;s skin to see if it turns red and bumpy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H269187174\">",
"      <span class=\"h1\">",
"       How are seasonal allergies treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Children with seasonal allergies might get 1 or more of the following treatments to help reduce their symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Nose rinses",
"        </strong>",
"        &ndash; Older children can try nose rinses. Rinsing out the nose with salt water cleans the inside of the nose and gets rid of pollen in the nose. This can also help to clear things out if the nose is very stuffed up. Different devices can be used to rinse the nose.",
"       </li>",
"       <li>",
"        <strong>",
"         Steroid nose sprays",
"        </strong>",
"        &ndash; Doctors often prescribe these sprays first, but it can take days to weeks before they work. (Steroid nose sprays do not contain the same steroids that athletes take to build muscle.) Your child&rsquo;s doctor will prescribe the safest dose for his or her age.",
"       </li>",
"       <li>",
"        <strong>",
"         Antihistamines",
"        </strong>",
"        &ndash; These medicines help stop itching, sneezing, and runny nose symptoms. Some antihistamines can make people feel tired, and should not be given to young children. Talk to your child&rsquo;s doctor before trying any new medicines.",
"       </li>",
"       <li>",
"        <strong>",
"         Allergy shots",
"        </strong>",
"        &ndash; Your child&rsquo;s doctor might suggest that he or she get allergy shots. Usually, allergy shots are given every week or month by an allergy doctor. These shots can help lower your child&rsquo;s risk of getting asthma later in life.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you want to try over-the-counter (nonprescription) medicines for your child, be sure to read the directions carefully. Some, like medicines used to treat a stuffy nose or red eyes, are not safe for young children.",
"     </p>",
"     <p>",
"      Talk with your child&rsquo;s doctor or nurse about the benefits and downsides of the different treatments. The right treatment for your child will depend a lot on his or her symptoms and other health problems. It is also important to talk with your child&rsquo;s doctor or nurse about when and how your child should take certain medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H269187189\">",
"      <span class=\"h1\">",
"       Can seasonal allergy symptoms be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child gets symptoms at the same time every year, talk with his or her doctor or nurse. Some people can prevent symptoms by starting their medicine a week or 2 before that time of the year.",
"     </p>",
"     <p>",
"      You can also help prevent symptoms by having your child avoid the things he or she is allergic to. For example, if your child is allergic to pollen, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep your child inside during the times of the year when he or she has symptoms",
"       </li>",
"       <li>",
"        Keep car and house windows closed, and use air conditioning instead",
"       </li>",
"       <li>",
"        Have your child take a bath or shower before bed to rinse pollen off the hair and skin",
"       </li>",
"       <li>",
"        Use a vacuum with a special filter (called a &ldquo;HEPA filter&rdquo;) to keep indoor air as clean as possible",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H269187204\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/38/37474?source=see_link\">",
"       Patient information: Seasonal allergies in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/18/16674?source=see_link\">",
"       Patient information: Rinsing out your nose with salt water (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=see_link\">",
"       Patient information: Allergy shots (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=see_link\">",
"       Patient information: Allergy skin testing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       Patient information: Asthma in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"       Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/40/5764?source=see_link\">",
"       Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/27/5553?source=see_link\">",
"       Patient information: Allergic conjunctivitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/10/13475?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87053 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13475=[""].join("\n");
var outline_f13_10_13475=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H269187072\">",
"      What are seasonal allergies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H269187110\">",
"      What are the symptoms of seasonal allergies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H269187159\">",
"      Is there a test for seasonal allergies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H269187174\">",
"      How are seasonal allergies treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H269187189\">",
"      Can seasonal allergy symptoms be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H269187204\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/59/23477\">",
"      Common causes of seasonal allergies",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24576\">",
"       Child with allergies",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"UTD.htm?20/23/20860\">",
"        Causes and symptoms of common allergies",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/27/5553?source=related_link\">",
"      Patient information: Allergic conjunctivitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=related_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=related_link\">",
"      Patient information: Allergy shots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=related_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/18/16674?source=related_link\">",
"      Patient information: Rinsing out your nose with salt water (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/38/37474?source=related_link\">",
"      Patient information: Seasonal allergies in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/40/5764?source=related_link\">",
"      Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_10_13476="Porfimer: Patient drug information";
var content_f13_10_13476=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Porfimer: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39157?source=see_link\">",
"     see \"Porfimer: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Photofrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Photofrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3509431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with light therapy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to porfimer or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, bright indoor lights, and tanning beds. Wear clothing and eyewear that protects you from the sun. Sunscreens will not protect you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throat irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12193 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13476=[""].join("\n");
var outline_f13_10_13476=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211474\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211475\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013881\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013880\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013885\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013886\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013888\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013883\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013890\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39157?source=related_link\">",
"      Porfimer: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_10_13477="Moclobemide: Patient drug information";
var content_f13_10_13477=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Moclobemide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=see_link\">",
"     see \"Moclobemide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Moclobemide&reg;;",
"     </li>",
"     <li>",
"      Dom-Moclobemide;",
"     </li>",
"     <li>",
"      Manerix&reg;;",
"     </li>",
"     <li>",
"      Novo-Moclobemide;",
"     </li>",
"     <li>",
"      Nu-Moclobemide;",
"     </li>",
"     <li>",
"      PMS-Moclobemide;",
"     </li>",
"     <li>",
"      Teva-Moclobemide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702541",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to moclobemide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Citalopram, fluvoxamine, paroxetine, or sertraline. Do not use within 2 weeks of other antidepressants.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pheochromocytoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use OTC drugs that have dextromethorphan or pseudoephedrine. They may cause very high blood pressure when used with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698132",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Confusion; very nervous; anger with sweating, shivering, stiffness, or shaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12035 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13477=[""].join("\n");
var outline_f13_10_13477=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197419\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020249\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020251\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020250\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020255\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020256\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020258\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020253\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020254\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020259\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020260\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=related_link\">",
"      Moclobemide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_10_13478="Bone marrow features of T-LGL leukemia";
var content_f13_10_13478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow features of T-cell large granular lymphocyte leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin staining of marrow biopsy reveals a slightly hypercellular marrow with subtle increase in interstitial lymphocytes, as shown by arrow (left). Immunohistochemistry analyses (right) highlight the presence of intrasinusoidal cytotoxic T-cell infiltrates, staining positive for CD8 (arrow) and granzyme B (inset). Micrographs were viewed with a Leica Leitz DMRB microscope using a 100x/1.30 oil immersion objective. Images were captured with a Sony Exwave HAD camera and manipulated using Tribyn Version 1.3 software.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764. Copyright &copy; 2011 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13478=[""].join("\n");
var outline_f13_10_13478=null;
var title_f13_10_13479="Acute ISN Low power";
var content_f13_10_13479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Low power light micrograph of kidney biopsy of a patient with severe acute interstitial nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of severe acute interstitial nephritis showing diffuse interstitial inflammatory infiltrate. One normal glomerulus is present at the top of the slide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13479=[""].join("\n");
var outline_f13_10_13479=null;
var title_f13_10_13480="Clinical trials of human papillomavirus vaccines";
var content_f13_10_13480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of human papillomavirus vaccines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/10/13480/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13480/contributors\">",
"     Philip E Castle, PhD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13480/contributors\">",
"     J Thomas Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13480/contributors\">",
"     Joel M Palefsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/10/13480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13480/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/10/13480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13480/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/10/13480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two vaccines have been developed against human papillomavirus (HPV) infection. One is a quadrivalent vaccine (Gardasil) and the other is a bivalent vaccine (Cervarix).",
"   </p>",
"   <p>",
"    Some of the major clinical trials that have been performed to date in males and females are discussed in detail below. The natural history, epidemiology, and immunology of HPV and indications for use of HPV vaccine in clinical practice are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26229?source=see_link\">",
"     \"The life cycle, natural history, and immunology of human papillomaviruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VACCINE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HPV L1 major capsid protein, when recombinantly expressed alone, can self-assemble into virus-like particles (VLPs) for each HPV type [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The HPV L1 VLPs do not contain the HPV viral genome or any other genetic material and therefore are rendered non-infectious and non-carcinogenic. Preclinical research demonstrated that L1 is highly immunogenic with and without an adjuvant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proof-of-concept vaccine trial with HPV 16 VLP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/4\">",
"     4",
"    </a>",
"    ] demonstrated that HPV 16 infection could be effectively prevented. In follow-up studies of this population, women were nearly completely protected against HPV 16 up to 8.5 years after HPV 16 vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two vaccines were subsequently developed and tested in phase III efficacy trials for use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An HPV vaccine that targets HPV 6, 11, 16, and 18 (quadrivalent HPV",
"      <span class=\"nowrap\">",
"       6/11/16/18",
"      </span>",
"      VLP vaccine) (Gardasil; Merck &amp; Co, Inc, Whitehouse Station, New Jersey)",
"     </li>",
"     <li>",
"      An HPV vaccine that targets HPV 16 and 18 (bivalent HPV",
"      <span class=\"nowrap\">",
"       16/18",
"      </span>",
"      VLP vaccine) (Cervarix; GlaxoSmithKline, Rixensart, Belgium)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TOOLS FOR ASSESSMENT OF VACCINE EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine efficacy is measured only by the prevention of virologic infection or related clinical events. The immunogenicity of the HPV vaccines is not equated with vaccine efficacy primarily because there is no established correlate between a titer level and protection against HPV infection or the development of cervical intraepithelial neoplasia (CIN) or cancer.",
"   </p>",
"   <p>",
"    Vaccine efficacy is defined for several natural history events that all serve as surrogate markers for the development of cervical cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Incident HPV infection",
"     </li>",
"     <li>",
"      Persistent type-specific HPV infection (&gt;6 or &gt;12 months)",
"     </li>",
"     <li>",
"      Abnormal cytology",
"     </li>",
"     <li>",
"      Abnormal histological changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measures of HPV infection and cervical abnormalities after immunization give complementary information. The best surrogate for cancer risk is histologically-confirmed cervical precancerous lesions,",
"    <span class=\"nowrap\">",
"     CIN2/3.",
"    </span>",
"    In contrast, abnormal cytology can be caused by many HPV genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/6\">",
"     6",
"    </a>",
"    ] and therefore is a relatively nonspecific endpoint for type-specific protection. In contrast, prevention of incident HPV infections provides evidence of type-specific effects of the vaccine, although most HPV infections will eventually clear in the immunocompetent host.",
"   </p>",
"   <p>",
"    Importantly, efficacy should not be confused with effectiveness or public health benefit. Efficacy is the reduction of endpoints in a selected trial population. A simple measure of public health benefit is the expected number of events (disease endpoints) averted per woman in a whole population of women (ie, \"all-comers\"). Unfortunately, the two metrics of vaccine impact are often (incorrectly) used interchangeably. Incident HPV infections at any age have a low risk of developing into clinically-relevant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/7\">",
"     7",
"    </a>",
"    ]; only prevalently-detected HPV infections, which are not impacted by HPV vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], are more likely to persist in older versus younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, while HPV vaccination in women over 26 is highly efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/12\">",
"     12",
"    </a>",
"    ], it prevents relatively fewer HPV infections and even fewer",
"    <span class=\"nowrap\">",
"     CIN2/3",
"    </span>",
"    compared with younger populations; these observations suggest that within this age group, HPV vaccination provides little (public health) benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     QUADRIVALENT HPV 6/11/16/18 L1 VIRUS-LIKE PARTICLE VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gardasil targets HPV genotypes 16 and 18, which are associated with the majority of cervical cancers and precancerous lesions (cervical intraepithelial neoplasia (CIN) grade 2 or 3) worldwide, and HPV genotypes 6 and 11, which are associated with the vast majority of genital warts. Gardasil has been evaluated in two large, randomized clinical trials named FUTURE (Females United To Unilaterally Reduce",
"    <span class=\"nowrap\">",
"     Endo/ectocervical",
"    </span>",
"    disease) II and I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy in females",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     The FUTURE II trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase III, multi-national prospective, double-blind, placebo-controlled trial (FUTURE II), more than 12,000 women, aged 15 to 26 years (mean age of 20 years), were randomly assigned to receive a three-dose regimen of vaccine or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/8\">",
"     8",
"    </a>",
"    ]. The majority of the study participants were from Europe (65 percent) and Latin America (26 percent). Women with greater than four lifetime sexual partners or a history of abnormal cytology were excluded from the study. Evidence of past or current infections with HPV 16",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HPV 18 (as measured by serology and DNA detection in cervical specimens) was found in approximately one-fourth of the women in the vaccine and placebo arms (23 and 28 percent, respectively) through one month follow-up after vaccination.",
"   </p>",
"   <p>",
"    The primary efficacy analysis (According-To-Protocol [ATP] analysis) was performed in those subjects who did not have evidence of either HPV 16 or 18 infection (by HPV DNA or HPV serological testing) through one month after the third dose of vaccine; these patients were referred to as \"HPV-naive\" as per protocol. The primary composite end point was the development of CIN 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV 16 or HPV 18 among the \"HPV-naive\" women. After a mean follow-up of three years, the following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccine efficacy, for the prevention of the primary composite end point, was 98 percent in study participants who were \"HPV-naive\".",
"     </li>",
"     <li>",
"      Vaccine efficacy remained high (95 percent) in those HPV-negative participants who did not receive all doses of vaccine according to protocol, suggesting some flexibility in the timing of the vaccine schedule.",
"     </li>",
"     <li>",
"      Seroconversion rates at 24 months among 1512 vaccinated women in the immunogenicity sub-study were 96, 97, 99, and 68 percent for HPV types 6, 11, 16, and 18, respectively.",
"     </li>",
"     <li>",
"      The vaccine was well tolerated; women who received the vaccine were more likely to have an injection site event (eg, erythema, pain, pruritus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling) than women receiving the placebo. A full discussion of adverse events associated with immunization, including the postmarketing experience, is found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H21#H21\">",
"       \"Recommendations for the use of human papillomavirus vaccines\", section on 'Vaccine safety'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, the vaccine efficacy in the intention-to-treat (ITT) analysis was significantly lower than in the according-to-protocol (ATP) analysis. Vaccine efficacy for CIN 2 or 3 disease due to all HPV types was significantly lower (44 percent) in the overall population of women who had undergone randomization, which included participants with baseline or incident HPV infection by one month after the last dose of vaccine. These results suggest limited cross-reactivity of protection and the importance of early vaccination before infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     The FUTURE 1 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similarly designed phase III placebo-controlled trial was conducted in 5455 women aged 16 to 24 years to assess the efficacy of quadrivalent vaccine to prevent HPV-related anogenital disease (FUTURE I) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/9\">",
"     9",
"    </a>",
"    ]. The majority of the study participants were from Latin America (41 percent) or North America (29 percent). Women with greater than four lifetime sexual partners or a history of any genital warts or abnormal cytology were excluded from the study. Evidence of past or current infection with one or more of the vaccine genotypes (HPV 6, 11, 16",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    18) as measured by serology and DNA detection in cervical specimens was found among women in the vaccine and placebo arms (38 and 42 percent, respectively) through one month follow-up after vaccination.",
"   </p>",
"   <p>",
"    The primary aim of the trial was to determine vaccine efficacy in reducing the combined endpoint of incidence of anogenital warts, vulvar intraepithelial neoplasia (VIN) or vaginal intraepithelial neoplasia (VAIN) grades 1 to 3 or cancer associated with HPV 6, 11, 16, or 18. A secondary aim was to observe whether the administration of vaccine reduced the combined incidence of CIN grades 1 to 3, adenocarcinoma in situ, or cancer associated with vaccine-type HPV. After a mean follow-up of three years, the following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vaccine was 100 percent effective in preventing anogenital disease in women who were \"HPV-naive\" (ie, no cases were identified in the vaccine group versus 60 cases in the placebo group).",
"     </li>",
"     <li>",
"      Vaccine efficacy was 100 percent in preventing CIN grades 1 to 3 or adenocarcinoma in situ caused by the vaccine-type HPVs in those women who were \"HPV-naive\" (ie, no cases were diagnosed in the vaccine group, whereas 65 cases were diagnosed in placebo group).",
"     </li>",
"     <li>",
"      The vaccine was well tolerated. However, women who received the vaccine were 10 percent more likely to experience an injection site event (erythema, pain, pruritus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling) and 3 percent more likely to experience an injection-related event (eg, fever) than women receiving the placebo. A full discussion of adverse events associated with immunization, including the postmarketing experience, is found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H21#H21\">",
"       \"Recommendations for the use of human papillomavirus vaccines\", section on 'Vaccine safety'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted in the FUTURE II trial, vaccine efficacy in the intention-to-treat group was lower compared with the according-to-protocol analysis in FUTURE I. Vaccine efficacy against lesions associated with any HPV genotype for all external lesions was 20 percent.",
"   </p>",
"   <p>",
"    A summary of the efficacy data from four placebo-controlled, double-blind, randomized Phase II and III clinical studies of the quadrivalent vaccine may also be viewed on the website for the US Food and Drug Administration (",
"    <a class=\"external\" href=\"file://www.fda.gov/\">",
"     www.fda.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184231\">",
"    <span class=\"h3\">",
"     Prevention of subsequent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A post-hoc subgroup analysis of pooled data from the two FUTURE trials evaluated the effect of the quadrivalent HPV vaccine on rates of HPV-related disease in women who developed genital disease despite vaccination. Among women who underwent cervical surgery for HPV-related disease, the incidence of subsequent CIN grade 2 or worse related to any HPV type was lower in the 474 who had received the vaccine compared with the 592 placebo recipients (1.1 versus 3.1 cases per 100 person years) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/13\">",
"     13",
"    </a>",
"    ]. Among women who had been treated for genital warts, or vaginal or vulvar intraepithelial neoplasia, vaccine recipients had lower rates of subsequent genital warts but the same rates of vulvar, vaginal, or CIN grade 2 or worse as placebo recipients. This study had several notable limitations. The mean follow-up was short (1.2 years), and there were few overall events. Furthermore, the retrospective analysis could not ensure that all events were new episodes as opposed to residual disease. Nevertheless, these results suggest that the vaccine may reduce the risk of subsequent HPV-related cervical disease in women with a history of CIN grade 2 or worse. Although the study demonstrated efficacy, there are no data on the population effectiveness or cost effectiveness to support vaccination of this subgroup.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cross-protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary combined analyses of data from the FUTURE I and II trials demonstrated partial protection against acquisition of the nonvaccine HPV types (HPV",
"    <span class=\"nowrap\">",
"     31/33/45/52/58)",
"    </span>",
"    that cause approximately 20 percent of cervical cancers. In HPV-na&iuml;ve women, infection rates due to these nonvaccine genotypes and related disease (eg,",
"    <span class=\"nowrap\">",
"     CIN1-3/adenocarcinoma",
"    </span>",
"    in situ) was 25 percent and 29 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/14\">",
"     14",
"    </a>",
"    ]. In sexually active women, the reductions in infections and related diseases were somewhat lower (eg, 18 and 19 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/15\">",
"     15",
"    </a>",
"    ]. In a subsequent analysis of the same data, the cross-protective efficacy of the quadrivalent vaccine among HPV-na&iuml;ve women appeared to be restricted to HPV 31 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Therapeutic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both FUTURE II and I trials, there was no evidence that vaccination altered the course of disease or infection in women who had evidence of HPV infection at the time of receipt of the first dose of vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These data reinforce the use of the HPV vaccine to prevent infection rather than as a therapeutic intervention to treat preexisting HPV infection and related diseases. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Vaccine immunogenicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Regulatory approval",
"    </span>",
"    &nbsp;&mdash;&nbsp;In June of 2006, the Food and Drug Administration approved the use of Gardasil in females 9 to 26 years of age and in October 2009 it was approved for males of the same age. Gardasil has also been approved for use in approximately 100 countries around the world, although the specific age recommendations are country dependent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Post-approval safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC) conducted a review of the adverse events following immunization (AEFI) for Gardasil between June 1, 2006 and December 1, 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/17\">",
"     17",
"    </a>",
"    ]. There were 12,424 reports of AEFIs following Gardasil distribution, or 53.9 reports per 100,000 doses distributed. The proportion of AEFI per vaccine dose was similar to those observed for other vaccines, but there was an increased reporting of syncope and venous thromboembolic events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H21#H21\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Vaccine safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BIVALENT HPV 16/18 L1 VIRUS-LIKE PARTICLE VACCINE",
"    </span>",
"   </p>",
"   <p>",
"    Cervarix is a bivalent vaccine that targets HPV genotypes 16 and 18, which are associated with the majority of cervical cancers and precancerous lesions",
"    <span class=\"nowrap\">",
"     (CIN2/3)",
"    </span>",
"    found worldwide; unlike Gardasil it does not target HPV 6 and 11. Cervarix has been evaluated in one large, randomized clinical trial named PATRICIA (Papilloma trial against cancer in young adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/18\">",
"     18",
"    </a>",
"    ] and an autonomous US National Cancer Institute (NCI)-sponsored trial in Costa Rica [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In PATRICIA, a phase III, multi-national prospective, double-blind, placebo-controlled trial, more than 18,000 women, aged 15 to 25 years (mean age of 20 years), were randomly assigned to receive a three-dose regimen of vaccine or a control",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/18\">",
"     18",
"    </a>",
"    ]. The majority of the study participants were from Europe (38 percent) and Asia Pacific (33 percent). Women with greater than six lifetime sexual partners or a history of colposcopy were excluded from the study. Approximately 26 percent of women in both arms had current or evidence of past infections by HPV 16 and HPV 18 (as measured by serology and DNA detection in cervical specimens through one month follow-up following vaccination).",
"   </p>",
"   <p>",
"    The primary efficacy analysis (According-To-Protocol [ATP] analysis) was performed in those subjects who did not have evidence of either HPV 16 or 18 infections (by HPV DNA or HPV serological testing) at enrollment and were HPV 16 and 18 DNA-negative at six months. The primary composite end point was the development of CIN 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV 16 or HPV 18. After a mean follow-up of three years, the following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccine efficacy for the prevention of the primary composite end point of CIN2, CIN3, adenocarcinoma in situ, or cancer was 93 percent.",
"     </li>",
"     <li>",
"      Vaccine efficacies for the prevention of incidentally-detected 6-month and 12-month persistent infections by HPV",
"      <span class=\"nowrap\">",
"       16/18",
"      </span>",
"      were 94 percent and 91 percent, respectively.",
"     </li>",
"     <li>",
"      The vaccine was well tolerated and there were no differences in the serious adverse events by study arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, the vaccine efficacy in the intention-to-treat (ITT) analysis was significantly lower than in the according-to-protocol analysis noted above. Vaccine efficacy for CIN2 or more severe disease due to all HPV types was significantly lower (30 percent) in the overall population of women who had undergone randomization, which included participants with baseline or incident HPV infection by one month after the last dose of vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cross-protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervarix demonstrated partial protection against acquisition of the nonvaccine HPV types (HPV",
"    <span class=\"nowrap\">",
"     31/33/45/52/58)",
"    </span>",
"    that cause approximately 20 percent of cervical cancers. In the according-to-protocol (ATP) population, the reductions in six-month persistent infection, 12-month persistent infection, and CIN2+ disease related to these genotypes were 30 percent, 24 percent, and 53 percent, respectively. However, in a systematic review of bivalent vaccine trials, the efficacy against infection with nonvaccine HPV types was lower in trials with longer follow-up periods, suggesting the possibility of waning cross-protection over time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Therapeutic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There was no evidence that HPV vaccination altered the course of vaccine-type HPV infections present before or at the administration of the first dose of vaccine in the NCI trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/10\">",
"     10",
"    </a>",
"    ]. These data reinforce the use of HPV vaccine to prevent infection rather than as a therapeutic intervention to treat preexisting HPV infection and related diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Regulatory approval",
"    </span>",
"    &nbsp;&mdash;&nbsp;On October 19, 2009, the US Food and Drug Administration (FDA) approved use of Cervarix in females 9 to 26 years of age. Cervarix has been approved for use in approximately 100 countries around the world, although specific age recommendations are country dependent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Post-approval safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VACCINE IMMUNOGENICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of primary immunogenicity of Gardasil demonstrated the following [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All of the subjects had detectable HPV 6, 11, 16, and 18 antibodies after completion of the vaccine series.",
"     </li>",
"     <li>",
"      Anti-HPV geometric mean titers (GMT) were 27- to 145-fold higher than those observed in placebo recipients who were HPV-seropositive at baseline, suggesting that HPV vaccine leads to higher antibody titers than natural infection.",
"     </li>",
"     <li>",
"      At 36 months of follow-up, vaccine-induced antibody titers were comparable or higher than those of natural infection.",
"     </li>",
"     <li>",
"      In the subset of seropositive women with detectable antibodies against vaccine types at baseline, HPV vaccine led to rapid inclines, higher peaks, and longer persistence of antibody levels compared with women who were seronegative for vaccine types, suggesting that HPV vaccine may induce anamnestic responses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly excellent antibody responses have been reported for Cervarix, with sustained high antibody concentrations after 6.4 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In a head-to-head comparison of the immunogenicity of the quadrivalent and bivalent HPV vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/23\">",
"     23",
"    </a>",
"    ], immunization by Cervarix induced geometric mean titers of serum neutralizing antibodies 2.3- to 4.8-fold higher for HPV 16 and 6.8- to 9.1-fold higher for HPV 18 across all age strata than did Gardasil. Whether the induction of higher serum titers against HPV 16 and 18 has any impact on the degree and duration of protection is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS OF HPV VACCINE IN MALES",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV infection is prevalent in men, affecting more than one-fourth to one-half of sexually active men, particularly those with multiple sex partners [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, the burden of HPV-associated diseases such as anal, penile, and oropharyngeal cancers in men is much less than that of cervical cancer in women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for including males in immunization programs has included protection of males from HPV-related diseases and to decrease sexual transmission of HPV from males to females. Clinical trials of HPV vaccine in males have demonstrated similar immunogenicity with a favorable side effect profile. The efficacy of HPV in preventing anal intraepithelial neoplasia in males is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Bivalent vaccine (Cervarix) in males",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase",
"    <span class=\"nowrap\">",
"     I/II,",
"    </span>",
"    observer-blind, parallel-group trial randomly assigned 270 Finnish boys (aged 10 to 18 years) in a 2:1 ratio to receive either bivalent HPV vaccine or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    as a control [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/27\">",
"     27",
"    </a>",
"    ]. At study entry, 11 percent of the participants were seropositive for HPV 16",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HPV 18 antibodies. The study demonstrated that the vaccine was highly immunogenic with 100 percent of the vaccinees attaining seroconversion for both HPV 16 and HPV 18 at two months and seven months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Quadrivalent vaccine (Gardasil) in males",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1041929\">",
"    <span class=\"h3\">",
"     Prevention of genital warts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized, double-blind trial, 1781 children, approximately half of whom were male, were assigned 2:1 to quadrivalent HPV vaccine or saline placebo to assess the tolerability and immunogenicity of the HPV vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/28\">",
"     28",
"    </a>",
"    ]. At month seven, seroconversion rates were &gt;99 percent for the four vaccine types (HPV 6, 11, 16, and 18) and geometric mean titers and seroconversion rates in boys were noninferior to those in girls.",
"   </p>",
"   <p>",
"    The efficacy and safety of three doses of Gardasil was also evaluated among 4065 boys and men from 16 to 26 years of age in a randomized double-blind international trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/29\">",
"     29",
"    </a>",
"    ]. A total of 3463 of the subjects were heterosexual and 602 had sex with male partners. The primary efficacy objective was to demonstrate that Gardasil reduced the incidence of external genital lesions (penile, scrotal and peri-anal) related to HPV-6, 11, 16, or 18 as compared with placebo. The secondary endpoint was to determine if immunization was protective against persistent HPV infection, which was defined as detection of the same HPV type (6, 11, 16, or 18) in an anogenital swab or biopsy specimen over a six-month time interval.",
"   </p>",
"   <p>",
"    Efficacy analyses were performed in a &ldquo;per-protocol population&rdquo;, represented by patients who did not have evidence of infection with the relevant HPV types at enrollment (ie, HPV 6, 11, 16, or 18) and who received all three doses of vaccine. Additional intention-to-treat analyses were also conducted for patients who received at least one dose of vaccine or placebo, regardless of baseline HPV status. A total of 175 subjects did not return for follow-up after their first dose and were eliminated from the analyses (with comparable numbers in each arm).",
"   </p>",
"   <p>",
"    The trial demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Within one month after the third dose of vaccine, seroconversion for HPV-6, 11, 16, and 18 occurred in more than 97 percent of participants randomly assigned to the vaccine arm.",
"     </li>",
"     <li>",
"      In the intention to treat population, 36 external genital lesions were seen in the vaccine group as compared with 89 in the placebo group for an overall efficacy rate of 60 percent (95% CI 41-74).",
"     </li>",
"     <li>",
"      In the per protocol population, vaccine efficacy for genital lesions related to HPV-6, 11, 16, or 18 was 90 percent (95% CI 69-98).",
"     </li>",
"     <li>",
"      Protection against persistent infection with vaccine HPV types was significantly higher among those patients who did not have HPV infection at baseline compared with those who did (86 versus 48 percent).",
"     </li>",
"     <li>",
"      Injection site pain was significantly higher among those receiving vaccine compared with placebo (57 versus 51 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the analysis of efficacy was broken down into low- and high-risk HPV types, the vaccine was associated with significant reductions in lesions related to HPV-6 and 11 and nonsignificant reductions in lesions related to HPV 16 and 18. However, the study design was limited by the short-term follow-up (median of 2.9 years) and the young age of the study population (since lesions, such as penile intraepithelial neoplasia, tend to occur later in life).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1041992\">",
"    <span class=\"h3\">",
"     Prevention of anal intraepithelial neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the HPV quadrivalent vaccine was effective in preventing genital warts in a clinical trial involving 4065 males [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/29\">",
"     29",
"    </a>",
"    ]. A planned substudy of that trial analyzed the impact of HPV vaccine on the development of anal intraepithelial neoplasia (AIN) in 602 men who have sex with men (MSM) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/30\">",
"     30",
"    </a>",
"    ]. The study population consisted of HIV-seronegative males aged 16 to 26 years who had a history of five or fewer lifetime sexual partners. The primary endpoint of the trial was the development of AIN associated with HPV types 6, 11, 16, or 18.",
"   </p>",
"   <p>",
"    Two separate analyses were performed. The intent to treat analysis included all participants, regardless of HPV positivity at baseline, who received at least one dose of vaccine and had at least one follow-up visit. In a separate per protocol analysis, events were analyzed among patients without evidence of HPV infection who completed the vaccine series. The trial demonstrated the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the intent-to-treat population, the overall incidence of AIN associated with HPV 6, 11, 16, or 18 declined by 50 percent among those receiving vaccine compared with placebo (6.3 versus 12.6 events per 100 person years at risk).",
"     </li>",
"     <li>",
"      The risk of persistent HPV infection with the relevant vaccine HPV types declined by 59 percent in the HPV vaccine recipients (8.8 versus 21.6 events per 100 person years at risk).",
"     </li>",
"     <li>",
"      In the per protocol population (n = 402), the incidence of AIN associated with HPV vaccine types declined by 78 percent and the risk of persistent HPV declined by 95 percent compared with those who received placebo. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this trial indicate that the use of the quadrivalent vaccine can decrease the incidence of AIN related to HPV 6, 11, 16 and 18 in MSM.",
"   </p>",
"   <p>",
"    The HPV vaccine has also been evaluated for secondary prevention of AIN in older HIV-uninfected MSM previously treated for AIN grade 2 or worse lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13480/abstract/31\">",
"     31",
"    </a>",
"    ]. In a retrospective chart review analysis of 202 such patients with a mean age of 40 years, the rate of subsequent detection of AIN grade 2 or worse was lower in the 88 men who received the quadrivalent HPV vaccine compared with the 114 who did not (10 versus 16 events per 100 person-years). The difference in incidence of AIN grade 2 or worse after vaccination was even more pronounced among those having baseline infection with oncogenic HPV types (15 versus 28 events per 100 person-years in the unvaccinated). The association of vaccination with decreased detection of AIN grade 2 or worse persisted for at least two years. Interpretation of this study was limited by significant clinical heterogeneity between the two groups. The use of the quadrivalent HPV vaccine in this population has yet to be evaluated in a randomized controlled trial. Moreover, there are no data on the population effectiveness or cost effectiveness to support vaccination of this subgroup. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"       \"Patient information: Human papillomavirus (HPV) vaccine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"       \"Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two vaccines have been developed to protect against HPV infection, including a quadrivalent vaccine that targets HPV 6, 11, 16, and 18 (Gardasil) and a bivalent vaccine that targets HPV 16 and 18 (Cervarix). HPV genotypes 16 and 18 are associated with the majority of cervical cancers and cervical intraepithelial neoplasias worldwide, and HPV genotypes 6 and 11 are associated with the vast majority of genital warts. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Vaccine development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gardasil has demonstrated efficacy against the development of cervical intraepithelial neoplasia (CIN) 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV 16 or HPV 18 among the \"HPV-naive\" women and genital warts secondary to HPV 6 or 11. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Quadrivalent HPV 6/11/16/18 L1 virus-like particle vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervarix has demonstrated efficacy against the development of CIN 2 or 3, adenocarcinoma in situ, or cervical cancer among HPV-naive women. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bivalent HPV 16/18 L1 virus-like particle vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that either HPV vaccine formulation alters the course of vaccine-type HPV infections present before immunization. These data reinforce the use of HPV vaccine to prevent infection rather than as a therapeutic intervention to treat preexisting HPV infection and related diseases. Maximal benefit of HPV immunization is therefore expected when individuals are vaccinated prior to onset of sexual activity or as soon as possible after sexual debut. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Quadrivalent HPV 6/11/16/18 L1 virus-like particle vaccine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Bivalent HPV 16/18 L1 virus-like particle vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gardasil has demonstrated efficacy against the development of genital warts and anal intraepithelial neoplasia related to HPV 6, 11, 16, and 18 in males. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical trials of HPV vaccine in males'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for use and adverse events related to HPV immunization are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vaccine efficacy is measured only by the prevention of virologic infection or related clinical events. The immunogenicity of the HPV vaccines is not equated with vaccine efficacy primarily because there is no established correlate between a titer level and protection against HPV infection or the development of cervical intraepithelial neoplasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tools for assessment of vaccine efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/1\">",
"      Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/2\">",
"      Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992; 89:12180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/3\">",
"      Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/4\">",
"      Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/5\">",
"      Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27:5612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/6\">",
"      Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66:10112.",
"     </a>",
"    </li>",
"    <li>",
"     Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of HPV persistence and CIN2/3: critical role of duration of infection. J Natl Cancer Inst 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/8\">",
"      FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/9\">",
"      Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/10\">",
"      Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/11\">",
"      Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/12\">",
"      Mu&ntilde;oz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/13\">",
"      Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012; 344:e1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/14\">",
"      Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/15\">",
"      Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/16\">",
"      Malag&oacute;n T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/17\">",
"      Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/18\">",
"      Paavonen J, Naud P, Salmer&oacute;n J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/19\">",
"      Herrero R, Hildesheim A, Rodr&iacute;guez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008; 26:4795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/20\">",
"      Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24:5571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/21\">",
"      Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/22\">",
"      GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/23\">",
"      Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/24\">",
"      Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/25\">",
"      Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007; 16:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/26\">",
"      Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 Suppl 3:S3/11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/27\">",
"      Pet&auml;j&auml; T, Ker&auml;nen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009; 44:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/28\">",
"      Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/29\">",
"      Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/30\">",
"      Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13480/abstract/31\">",
"      Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012; 54:891.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8290 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13480=[""].join("\n");
var outline_f13_10_13480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VACCINE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TOOLS FOR ASSESSMENT OF VACCINE EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      QUADRIVALENT HPV 6/11/16/18 L1 VIRUS-LIKE PARTICLE VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy in females",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - The FUTURE II trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - The FUTURE 1 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184231\">",
"      - Prevention of subsequent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cross-protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Therapeutic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Regulatory approval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Post-approval safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BIVALENT HPV 16/18 L1 VIRUS-LIKE PARTICLE VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cross-protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Therapeutic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Regulatory approval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Post-approval safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VACCINE IMMUNOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CLINICAL TRIALS OF HPV VACCINE IN MALES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Bivalent vaccine (Cervarix) in males",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Quadrivalent vaccine (Gardasil) in males",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1041929\">",
"      - Prevention of genital warts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1041992\">",
"      - Prevention of anal intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26229?source=related_link\">",
"      The life cycle, natural history, and immunology of human papillomaviruses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_10_13481="Tattoo sarcoidosis";
var content_f13_10_13481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis involving a tattoo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy proven sarcoidosis involving only the tattooed skin. Firm papules are present within the tattooed areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13481=[""].join("\n");
var outline_f13_10_13481=null;
var title_f13_10_13482="Overview of ovulation induction";
var content_f13_10_13482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of ovulation induction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/10/13482/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13482/contributors\">",
"     Bart CJM Fauser, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/10/13482/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13482/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13482/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/10/13482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/10/13482/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/10/13482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovulatory disorders can be identified in the woman in 18 to 25 percent of couples presenting with infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of these women have oligomenorrhea, arbitrarily defined as menstruation that occurs at intervals of 35 days to six months. While ovulation may occasionally occur, spontaneous conception is unlikely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Induction of ovulation in these women is aimed at inducing monofollicular development, subsequent ovulation and ultimately pregnancy and birth of a healthy newborn (",
"    <a class=\"graphic graphic_figure graphicRef61116 \" href=\"UTD.htm?4/3/4158\">",
"     figure 1",
"    </a>",
"    ). Induction of ovulation should be differentiated from stimulation of multiple follicle development in ovulatory women (usually referred to as controlled ovarian hyperstimulation [CO]), as is done with assisted conception techniques. The method of ovulation induction selected by the clinician should be based upon the underlying cause of anovulation and the efficacy, costs, risks, and potential complications associated with each method as they apply to the individual woman.",
"   </p>",
"   <p>",
"    This topic will review the efficacy of the different regimens that are used (antiestrogens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , gonadotropins, pulsatile GnRH therapy, aromatase inhibitors, opiate antagonists, and dopamine agonists) and provide our approach to the management of such women. Some of these drugs are reviewed in greater detail elsewhere, and assisted conception techniques are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=see_link\">",
"     \"Ovulation induction with aromatase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANOVULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical approach to ovulation induction requires an understanding of the causes of anovulation. The classification adopted by the World Health Organization (WHO) provides a practical guide to appropriate therapeutic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     WHO class 1: Hypogonadotropic hypogonadal anovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder is also referred to as hypothalamic amenorrhea. Women in this group, which accounts for 5 to 10 percent of anovulatory women, usually have amenorrhea (although a range of gonadal compromise can be seen) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/2\">",
"     2",
"    </a>",
"    ]. They have low or low-normal serum follicle-stimulating hormone (FSH) concentrations and low serum estradiol concentrations due to decreased hypothalamic secretion of gonadotropin-releasing hormone (GnRH) or pituitary unresponsiveness to GnRH.",
"   </p>",
"   <p>",
"    The causes of hypothalamic amenorrhea include stress- or exercise-related amenorrhea, anorexia nervosa, and congenital GnRH deficiency (called Kallmann syndrome when anosmia is also present); approximately 5 to 10 percent have hypopituitarism. Reversing the lifestyle factors that contribute to the anovulation (low weight, heavy exercise) should be attempted before considering intervention with medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     WHO class 2: Normogonadotropic normoestrogenic anovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with normogonadotropic normoestrogenic anovulation constitute the largest group of anovulatory women encountered in clinical practice (70 to 85 percent of cases). Most women in this group have polycystic ovary syndrome. FSH and estrogen levels are normal, whereas LH concentrations may either be normal or elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/3\">",
"     3",
"    </a>",
"    ]. The criteria for diagnosis have been revised, although controversy remains (",
"    <a class=\"graphic graphic_table graphicRef54308 \" href=\"UTD.htm?1/21/1371\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some ovulate occasionally, especially those with oligomenorrhea. In obese women with PCOS, weight loss, which restores spontaneous ovulation in many women, should be attempted before treatment with ovulation induction agents is considered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, women with PCOS should be screened for impaired glucose intolerance before starting ovulation induction, because of the associated risk of pregnancy complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     WHO class 3: Hypergonadotropic hypoestrogenic anovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypergonadotropic hypoestrogenic anovulation accounts for 10 to 30 percent of cases of anovulation. The primary causes are primary ovarian insufficiency (absence of ovarian follicles due to early menopause) or in rare occasions ovarian resistance (follicular form) (",
"    <a class=\"graphic graphic_table graphicRef74029 \" href=\"UTD.htm?43/47/44795\">",
"     table 2",
"    </a>",
"    ). Many of these women have amenorrhea and they usually do not respond to therapy for anovulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperprolactinemic anovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperprolactinemia accounts for 5 to 10 percent of women with anovulation. These women are anovulatory because hyperprolactinemia inhibits gonadotropin and therefore estrogen secretion. Most have oligomenorrhea or amenorrhea. Their serum gonadotropin concentrations are usually normal or decreased.",
"   </p>",
"   <p>",
"    The presence of hyperprolactinemia should always be confirmed by several measurements of serum prolactin. An MRI of the head should be done in any woman with hyperprolactinemia in whom the cause is not obvious (eg, neuroleptic drug therapy, primary hypothyroidism). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANTIESTROGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1958, the nonsteroidal antiestrogen MER-25 was found to induce menstruation in an amenorrheic woman receiving the drug as an experimental treatment for endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/7\">",
"     7",
"    </a>",
"    ]. The next year, 43 anovulatory women given another antiestrogen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate, also ovulated.",
"   </p>",
"   <p>",
"    The mechanism of action of antiestrogens remains poorly understood. These agents are thought to occupy estrogen receptors in the hypothalamus and pituitary, thereby blocking the negative feedback action of estradiol. Consequently, serum FSH concentrations rise by around 50 percent, resulting in the stimulation of follicle growth and follicular estradiol production. However, other mechanisms, such as induced changes in the insulin-like growth factor system and SHBG levels, may also contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clomiphene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate (CC) is the most widely used antiestrogen for ovulation induction and is most effective in normogonadotropic anovulatory women (WHO class 2), ie, women with polycystic ovary syndrome. Ovulation induction with clomiphene is reviewed in detail elsewhere (including details from the 2006 Practice Committee report from the American Society of Reproductive Medicine). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"     \"Strategies for improving the efficacy of clomiphene induction of ovulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'Clomiphene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    , is a nonsteroidal antiestrogen capable of inducing ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/10\">",
"     10",
"    </a>",
"    ]. However, it has less of an antiestrogenic effect at the uterine level. The usual starting dose is 20 mg daily given for five days starting on day three to five of the cycle. In a randomized comparison between tamoxifen and clomiphene, no significant difference between ovulation and pregnancy rates were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of antiestrogen therapy is to induce mono-ovulation. There are a number of methods to suggest or confirm ovulation including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A biphasic basal body temperature (BBT)",
"     </li>",
"     <li>",
"      Resumption of regular menstrual cyclicity",
"     </li>",
"     <li>",
"      Evidence of a preovulatory increase in urinary LH on a home monitoring kit",
"     </li>",
"     <li>",
"      An elevated serum progesterone concentration during the mid-luteal phase of the cycle",
"     </li>",
"     <li>",
"      Pelvic ultrasound evidence of preovulatory follicular growth followed by collapse of the follicle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages and disadvantages of these methods are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transvaginal ultrasound can also be used to monitor for the presence of multiple follicular development, and the potential risk of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS). Some advocate ultrasound monitoring of just the first CC cycle in order to exclude multiple follicular development [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical outcomes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate are reviewed in detail elsewhere, but will be summarized here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sixty to 85 percent of anovulatory women ovulate in response to CC (most typically WHO class 2 patients, or women with polycystic ovary syndrome). Of those who ovulate, approximately 50 percent do so at a dose of 50 mg. Predictors of ovulation include a lower free androgen index (FAI), a calculation of testosterone not bound to SHBG, lower body mass index (BMI), presence of oligoamenorrhea (as opposed to amenorrhea) and lower ovarian volume. Of those who ovulate, 30 to 40 percent conceive. Predictors of pregnancy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    include younger age, low BMI, low FAI, and oligomenorrhea rather than amenorrhea. A nomogram has been developed to help predict chances for live birth based upon simple, initial screening characteristics (",
"    <a class=\"graphic graphic_figure graphicRef81180 \" href=\"UTD.htm?11/31/11775\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After six months of treatment, the pregnancy rate per cycle falls substantially despite regular ovulation. In addition, pregnancy rates are lower among women who ovulate only after receiving higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    . Failure to conceive despite ovulatory cycles, particularly at higher doses, may be due to clomiphene's antiestrogenic effects on the quantity and quality of cervical mucus and on the endometrium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Twin and triplet gestations occur in approximately 7 to 9 and 0.3 percent, respectively, of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -induced pregnancies. The incidence of miscarriage and birth defects appears to be similar to that in spontaneous pregnancies, and the rate of ectopic pregnancy is probably not increased. The risk of ovarian hyperstimulation syndrome is less than 1 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Addition of metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of hyperinsulinemia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    has been shown to have a beneficial effect in anovulatory women with PCOS by increasing menstrual cyclicity and improving spontaneous ovulation. However, it does not appear to improve live birth rates when given alone or in combination with CC. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link&amp;anchor=H14#H14\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Anovulatory infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors are a class of drugs that block the conversion of testosterone and androstenedione to estradiol and estrone, respectively (unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    which blocks estrogen action), thereby reducing negative estrogenic feedback at the pituitary and thus increasing FSH output. In contrast to CC, they appear to be free of the adverse effects on endometrial and cervical mucus attributed to clomiphene citrate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary studies have demonstrated that aromatase inhibitors are effective for ovulation induction or augmentation of ovulation in WHO 2 anovulatory women. However, a large clinical trial directly comparing aromatase inhibitors to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    is necessary to better define the risks and benefits of each method of ovulation induction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aromatase inhibitors are not approved for ovulation induction and may have fetal toxicity. Because clinical data are limited, we do not yet recommend the use of aromatase inhibitors for ovulation induction. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=see_link\">",
"     \"Ovulation induction with aromatase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GONADOTROPIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since their introduction into clinical practice in 1961, gonadotropins extracted from the urine of postmenopausal women (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12565?source=see_link\">",
"     human menopausal gonadotropins",
"    </a>",
"    [hMG]), in which the ratio of LH to FSH bioactivity is 1:1, have assumed a central role in ovulation induction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/15\">",
"     15",
"    </a>",
"    ]. Refinement of the initially crude preparation resulted in the availability of purified and highly purified urinary FSH. Since 1996, recombinant human FSH (rFSH, &gt;99 percent purity) has been available. Recombinant preparations are appealing due to their ease of administration (subcutaneous rather than intramuscular), purity, and batch-to-batch consistency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several indications for gonadotropin therapy in anovulatory women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normogonadotropic (WHO class 2) anovulatory women who have not ovulated or conceived with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      treatment.",
"     </li>",
"     <li>",
"      Hypogonadotropic (WHO class 1) anovulatory women with hypopituitarism or as second-line therapy in women with hypothalamic amenorrhea (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Pulsatile GnRH therapy'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of ovulation induction with gonadotropins, as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    , is the formation of a single dominant follicle. In spontaneous cycles, this is achieved at the beginning of the cycle by a transient increase in serum FSH concentrations above the threshold value [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/16\">",
"     16",
"    </a>",
"    ]. The concentrations then decrease due to negative feedback, preventing more than one follicle from undergoing preovulatory development (",
"    <a class=\"graphic graphic_figure graphicRef60133 \" href=\"UTD.htm?38/55/39805\">",
"     figure 3",
"    </a>",
"    ). Because ovarian sensitivity to FSH stimulation varies among individual women, specific treatment and monitoring protocols are needed to achieve development of a single follicle when exogenous gonadotropin is administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Step-up protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the conventional gonadotropin protocol, the starting dose of FSH is 150 int.",
"    <span class=\"nowrap\">",
"     units/day.",
"    </span>",
"    However, this regimen is associated with a multiple pregnancy rate of up to 36 percent and ovarian hyperstimulation occurs in up to 14 percent of treatment cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with PCOS, who are at particular risk for complications, this approach has been largely abandoned in favor of a",
"    <strong>",
"     low-dose, step-up protocol",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/17\">",
"     17",
"    </a>",
"    ] designed to allow the FSH threshold to be reached gradually, minimizing excessive stimulation and therefore the risk of development of multiple follicles. In this protocol, the initial subcutaneous or intramuscular dose of FSH is 37.5 to 75 int.",
"    <span class=\"nowrap\">",
"     units/day.",
"    </span>",
"    It is recommended that the dose is increased only if, after 14 days, no response is documented on ultrasonography and serum estradiol monitoring. Increments of 37.5 int. units then are given at weekly intervals up to a maximum of 225 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef58611 \" href=\"UTD.htm?31/18/32045\">",
"     figure 4",
"    </a>",
"    ). The optimal interval for increasing the dose has not been well studied in PCOS patients.",
"   </p>",
"   <p>",
"    The detection of an ovarian response is an indication to continue the current dose [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] until",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG) can be given to trigger ovulation, as described below (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Preparations'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Step-down protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low-dose step-down protocol of ovulation induction mimics more closely the physiology of normal cycles (",
"    <a class=\"graphic graphic_figure graphicRef52595 \" href=\"UTD.htm?3/26/3502\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/21\">",
"     21",
"    </a>",
"    ]. Therapy with 150 int. units",
"    <span class=\"nowrap\">",
"     FSH/day",
"    </span>",
"    is started shortly after spontaneous or progesterone-induced bleeding and continued until a dominant follicle (&gt;10 mm) is seen on transvaginal ultrasonography. The dose is then decreased to 112.5 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    followed by a further decrease to 75 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    three days later, which is continued until hCG is administered to induce ovulation. The appropriate starting dose can be determined by using the low-dose step-up regimen for the first treatment cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree to which the type of FSH compound employed may influence outcome of ovulation induction remains the subject of controversy. Two meta-analyses comparing the effectiveness of daily urinary FSH (uFSH) to daily human menopausal gonadotropin (HMG) for inducing ovulation in women with PCOS who had not responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate demonstrated no difference in pregnancy rate per treatment cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the women given FSH were less likely to have ovarian hyperstimulation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of randomized controlled trials comparing recombinant human FSH (rhFSH) with uFSH for ovulation induction in women with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate-resistant PCOS, no significant differences were demonstrated for the ovulation rate (OR 1.19; 95% CI 0.78-1.80). Furthermore, the odds ratios for pregnancy rate (0.95; 95% CI 0.64-1.41), miscarriage rate (1.26; 95% CI 0.59-2.70), multiple pregnancy rate (0.44; 95% CI 0.16-1.21), and for ovarian hyperstimulation syndrome (1.55; 95% CI 0.50-4.84) showed no significant difference between rhFSH and uFSH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Purified urinary FSH has some LH activity, but rFSH does not. The experience with rFSH in hypogonadotropic hypogonadal women (WHO class 1) indicates that those women who have very low serum LH concentrations (&lt;0.5 int.",
"    <span class=\"nowrap\">",
"     units/L)",
"    </span>",
"    need exogenous hCG (or 75 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    sc recombinant LH) to maintain adequate estradiol biosynthesis and follicle development [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-acting recombinant FSH preparations are currently registered in some countries for use in IVF [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/27\">",
"     27",
"    </a>",
"    ], but its use is not advised for ovulation induction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     Human chorionic gonadotropin",
"    </a>",
"    (hCG) is used to trigger ovulation when the ovarian follicles are mature. Both urinary and recombinant hCG preparations are available. A dose of 250 mcg of recombinant hCG appears to be equivalent to the standard doses of urinary hCG (5000 to 10,000 units) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other ovulatory triggers, such as recombinant LH, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovarian response to gonadotropin therapy is monitored using transvaginal ultrasonography to measure follicular diameter. The scans during the late follicular phase, usually performed every two or three days, should be focused on identifying follicles of intermediate size.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     Human chorionic gonadotropin",
"    </a>",
"    (hCG) is given on the day that at least one follicle appears to be mature. The criteria for follicle maturity are a follicle diameter of 18 mm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a serum estradiol concentration of 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (734",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    per dominant follicle. Available hCG preparations are reviewed in the preceding section (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Preparations'",
"    </a>",
"    above). If three or more follicles larger than 15 mm are present, stimulation should be stopped, hCG withheld, and use of a barrier contraceptive advised in order to prevent multiple pregnancies and ovarian hyperstimulation. Measurements of serum estradiol are useful; preovulatory concentrations above the normal range may predict ovarian hyperstimulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22647?source=see_link\">",
"     \"Prevention of ovarian hyperstimulation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=see_link\">",
"     \"Neonatal outcome, complications, and management of multiple births\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum progesterone measurements are sometimes useful before administration of hCG to determine if a premature LH surge has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of 225 women with PCOS treated over a 10-year period in one center found rates of ovulation and pregnancy of 72 percent and 45 percent, respectively, after use of the low-dose step-up protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/17\">",
"     17",
"    </a>",
"    ]. Multiple folliculogenesis and ovarian hyperstimulation are less common than that seen with the standard protocol, and pregnancy rates appear similar [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. However, the results of the low-dose step-up protocol are negatively influenced by age and obesity.",
"   </p>",
"   <p>",
"    Studies assessing outcomes with the step-down protocol have employed varied inclusion criteria and treatment protocols, which may explain why data comparing the step-down protocol and the low-dose step-up protocol have shown inconsistent results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In single-center studies, the step-down protocol appeared to be accompanied by a lower incidence of ovarian hyperstimulation and a higher incidence of monofollicular growth, thereby reducing the risk of multiple pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a multicenter study reported that the step-up protocol was more efficient in inducing monofollicular development and was associated with less ovarian hyperstimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/34\">",
"       34",
"      </a>",
"      ]. However, it has been argued that explanations for these results could be that most clinicians were less familiar with the step-down protocol and that higher initial doses were used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experience to date has indicated that the major drawback of the step-down regimen is that the initial starting dose is too high for some patients. In an effort to overcome this problem, sequential low-dose step-up and step-down regimens have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/35\">",
"     35",
"    </a>",
"    ]. This approach requires further evaluation.",
"   </p>",
"   <p>",
"    Gonadotropin therapy after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    treatment has failed has been the \"classical\" approach to ovulation induction for anovulatory infertility. Using this sequential approach, cumulative singleton live birth rates of 71 percent (only 7 percent multiples) over 24 months have been reported (",
"    <a class=\"graphic graphic_figure graphicRef66367 \" href=\"UTD.htm?11/63/12286\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/36\">",
"     36",
"    </a>",
"    ]. These results suggest that conventional approaches offer an effective means of treating the majority of women with anovulatory infertility before proceeding to more aggressive treatments such as in vitro fertilization.",
"   </p>",
"   <p>",
"    Ovulation induction is often combined with IUI, although this clinical approach is not based on sound clinical evidence.",
"   </p>",
"   <p>",
"    Obesity and insulin resistance (but not an elevated serum LH concentration) are associated with lower success rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Multiple gestation and ovarian hyperstimulation syndrome (OHSS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of multiple gestation is increased with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate, but to a greater extent with gonadotropin therapy. The reasons for multiple gestation and strategies to lower risk are described in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=see_link&amp;anchor=H14#H14\">",
"     \"Strategies to control the rate of high order multiple gestation\", section on 'Limiting the multiple gestation risk of ovulation induction and superovulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=see_link\">",
"     \"Neonatal outcome, complications, and management of multiple births\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OHSS is a potentially life-threatening complication of ovulation induction. Its most severe manifestations include massive ovarian enlargement and multiple cysts, hemoconcentration, and third-space accumulation of fluid; these changes may be complicated by renal failure, hypovolemic shock, thromboembolic episodes, acute respiratory distress syndrome, and death. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35479?source=see_link\">",
"     \"Classification and treatment of ovarian hyperstimulation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22647?source=see_link\">",
"     \"Prevention of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adjuvant treatment with GnRH analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant GnRH analogue treatment aimed at preventing premature luteinization has been proposed to improve outcomes in gonadotropin ovulation induction. However, insufficient data are available to conclude whether GnRH agonists may improve pregnancy or OHSS rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, there are insufficient data to draw conclusions regarding the possible role of GnRH antagonists as adjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CANCER RISK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of fertility drugs has been associated with neoplasia, particularly borderline ovarian tumors, in some [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/40-42\">",
"     40-42",
"    </a>",
"    ], but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Studies to date have focused on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    and gonadotropin therapy. In one study, the risk appeared to be only in women who had undergone more than 12 cycles of clomiphene citrate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of four case-control studies and four retrospective cohort studies, as well as three large meta-analyses including additional studies found that infertility treatment did",
"    <strong>",
"     not",
"    </strong>",
"    independently increase the risk for ovarian cancer; however, infertility itself was an independent risk factor for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/42,43,47-49\">",
"     42,43,47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the apparent association between fertility drug use and epithelial ovarian cancer appears to be related to the fact that these drugs are more likely to be used in infertile women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/41,50\">",
"     41,50",
"    </a>",
"    ]. This hypothesis is supported by the observation that nulliparous women with refractory infertility may harbor a particularly high risk of epithelial ovarian cancer, irrespective of their use of fertility drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns that ovarian cancer risk is associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    for more than 12 months has led to it being licensed for just six months of use in some countries. In the US, the American College of Obstetricians and Gynecologists has suggested that clomiphene treatment be limited to fewer than 12 cycles and that the number of gonadotropin cycles be minimized as well [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be an increased risk of breast cancer in women treated with fertility drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/44,45,54-58\">",
"     44,45,54-58",
"    </a>",
"    ]. However, interpretation of the available data is limited by several factors, such as survey information, small subgroup numbers, lack of evaluation by drug",
"    <span class=\"nowrap\">",
"     type/dose",
"    </span>",
"    or cause of infertility, and confounding by the presence of other risk factors for breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One relatively large case-control study showed that infertile women with breast cancer were more likely to have been treated with human menopausal gonadotropin (hMG) for more than six cycles than infertile women without breast cancer; no increased risk was noted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/59\">",
"     59",
"    </a>",
"    ]. However, this study was subject to many of the limitations noted above.",
"   </p>",
"   <p>",
"    In contrast, in a prospective cohort study of 116,671 women with 1357 incident cases of breast cancer, women who reported infertility due to an ovulatory disorder had a lower risk of breast cancer than women who did not report infertility (HR 0.75) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/60\">",
"     60",
"    </a>",
"    ]; women who had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate were at lowest risk (HR 0.60). In a sister-matched case-control study among approximately 1400 women with and 1600 sisters without breast cancer, those who had used clomiphene citrate or exogenous FSH but did not conceive were at lower risk of breast cancer compared with nonusers (OR 0.62, 95% CI 0.43-0.89). Those who used fertility drugs and did conceive (at least a 10-week pregnancy) had the same breast cancer risk as women who had never taken fertility drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, women taking infertility drugs can be reassured that these drugs probably do not increase their risk of breast cancer, although it is not clear whether some subgroups may be at increased risk. Further investigation is required.",
"   </p>",
"   <p>",
"    Other ovulation induction therapies discussed below (including pulsatile GnRH, opioid antagonists, and dopamine agonists) have not been linked to ovarian or breast cancer risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large population-based study found that childhood tumor risk was not increased in children conceived following ovulation induction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/62\">",
"     62",
"    </a>",
"    ]. Ongoing monitoring of the long-term effects of these drugs is warranted since the number of cases was small. Pregnancy outcome after assisted reproductive technologies is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective, cohort study, neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    nor gonadotropin use appeared to be associated with an increased risk of melanoma, thyroid, cervical, or colon cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/63\">",
"     63",
"    </a>",
"    ]. In contrast, the same investigators reported that clomiphene use may be associated with a greater risk of endometrial cancer. However, one explanation for these findings is that infertile women who used clomiphene were more likely to have underlying chronic anovulation, which is a strong risk factor for development of endometrial cancer, than infertile women not exposed to clomiphene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link&amp;anchor=H26#H26\">",
"     \"Ovulation induction with clomiphene citrate\", section on 'Uterine cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PULSATILE GnRH THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulsatile administration of GnRH using an infusion pump stimulates the production of endogenous FSH and LH. The resulting serum FSH and LH concentrations remain within the normal range, so the chances of multifollicular development and ovarian hyperstimulation are low. In comparison, continuous GnRH therapy lowers gonadotropin release (",
"    <a class=\"graphic graphic_figure graphicRef51212 \" href=\"UTD.htm?19/58/20398\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Indication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsatile GnRH administration is indicated for women with hypogonadotropic hypogonadal anovulation (WHO class 1) who have normal pituitary function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous route appears superior to the subcutaneous route. In order to mimic the normal pulsatile release of GnRH, the pulse interval is 60 to 90 minutes and the dose is 2.5 to 10 mcg per pulse [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The lower dose should be used initially in order to minimize the likelihood of multiple pregnancies; the dose should then be increased to the minimum dose required to induce ovulation. Pulsatile GnRH administration may be discontinued after ovulation, and the corpus luteum supported by hCG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular menstruation occurring approximately every four weeks indicates that the woman is having ovulatory cycles. Ultrasonography and measurements of serum progesterone are not usually needed for monitoring therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovulation rates of 90 percent and pregnancy rates of 80 percent have been reported in women treated with pulsatile GnRH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/67\">",
"     67",
"    </a>",
"    ]. Local complications such as phlebitis may occasionally occur.",
"   </p>",
"   <p>",
"    Pulsatile GnRH is currently unavailable in the US, but is widely used in other parts of the world. A smaller infusion device has been recently introduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     DOPAMINE AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonist drugs enhance the tonic suppression of prolactin synthesis and release from the pituitary, substituting for or supplementing endogenous dopamine.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     Bromocriptine",
"    </a>",
"    , the first dopamine agonist drug to prove effective in the treatment of hyperprolactinemia, remains in widespread use. Drugs that bind more specifically to dopamine D2 receptors on the lactotroph cells, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    , are associated with fewer side effects. The safety of bromocriptine with regard to teratogenesis is much better established than that of cabergoline, so many clinicians and patients prefer bromocriptine to attempt pregnancy, but patients who have severe side effects from bromocriptine prefer cabergoline.",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    has been associated with a dose-dependent increase in valvular heart disease. Although most cases have occurred in patients taking high dose cabergoline for Parkinson's disease, long-term use of relatively low doses for hyperprolactinemia may also be associated with excess risk.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/23/42355?source=see_link\">",
"     Quinagolide",
"    </a>",
"    is a nonergot dopamine agonist alternative that is available in some countries, but not the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\", section on 'Valvular heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Indication and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dopamine agonist is the treatment of choice for women with hyperprolactinemic anovulation. In women with a lactotroph adenoma, as an example, a marked reduction in the serum prolactin concentration occurs within two to three weeks (",
"    <a class=\"graphic graphic_figure graphicRef72539 \" href=\"UTD.htm?28/2/28717\">",
"     figure 8",
"    </a>",
"    ). The doses usually given are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      , start with 1.25 mg at bedtime for one week, then 1.25 mg twice a day for one month. If the serum prolactin concentration does not fall to near-normal or normal by then, the dose can be increased to 2.5 mg twice a day and, if necessary, to 5.0 mg twice a day.",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      start at 0.25 twice a week. If the serum prolactin concentration is not normal after one to two months, the dose can be increased to 0.5 mg twice a week or, if necessary, 1.0 mg twice a week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/23/42355?source=see_link\">",
"     quinagolide",
"    </a>",
"    , start at a dose of 0.025 mg per day and increase to 0.075 mg per day over seven days. This dose is maintained for at least one month until an evaluation of clinical effects and prolactin measurements is performed.",
"   </p>",
"   <p>",
"    Treatment should be stopped once pregnancy has been diagnosed, because the safety of continued usage has not been established. If the patient has a macroadenoma and the size increases enough to cause visual field impairment during pregnancy, treatment can be resumed then, but the need to do so is rare, especially if the patient is advised not to attempt to become pregnant while the adenoma is near the optic chiasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41510?source=see_link\">",
"     \"Management of lactotroph adenoma (prolactinoma) during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of regular menstrual cycles during treatment indicates that the woman is ovulating. Serum progesterone may be measured because luteal phase insufficiency has been associated with hyperprolactinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following correction of hyperprolactinemia, approximately 80 percent of women will ovulate and pregnancy rates of 70 to 80 percent can be achieved (",
"    <a class=\"graphic graphic_table graphicRef68772 \" href=\"UTD.htm?11/4/11339\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC OVARIAN DIATHERMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic ovarian diathermy represents an alternative second line therapy for women with PCOS. In women who are still anovulatory despite an adequate trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate, another therapeutic option next to gonadotropins is laparoscopic surgery with electrocautery or laser. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=see_link\">",
"     \"Laparoscopic surgery for ovulation induction in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     PRIMARY OVARIAN INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian function ceases (WHO class 3) in 1 percent of women before the age of 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/69\">",
"     69",
"    </a>",
"    ]. This condition is currently referred to as primary or premature ovarian insufficiency (POI). In most women, the follicle pool is exhausted due to accelerated follicle loss of unknown origin (",
"    <a class=\"graphic graphic_table graphicRef74029 \" href=\"UTD.htm?43/47/44795\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/70\">",
"     70",
"    </a>",
"    ]. In the resistant ovary syndrome, follicles remain but are unresponsive to FSH stimulation due, as an example, to antibodies against FSH or the FSH receptor or to a mutation in the gene for the FSH receptor. Medical treatment of anovulation in this group is rarely successful. Many strategies, including pretreatment suppression with exogenous estrogen or GnRH agonists have been proposed with the aim of improving outcomes from ovulation induction, but none have been successful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only effective option is treatment by in vitro fertilization of donor oocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical treatment for anovulatory infertility (ie, ovulation induction) should be differentiated from &ldquo;controlled ovarian hyperstimulation&rdquo; (for longstanding infertility or intrauterine insemination) or for in vitro fertilization because the women, the treatment goals, and clinical outcome are distinctly different.",
"   </p>",
"   <p>",
"    Despite this, a trend can be observed toward hyperstimulation and assisted reproduction as first line treatment in anovulatory infertility, especially PCOS. If carried out using single embryo transfer, this approach can reduce the risk of multiple pregnancy. However, the present shift towards IVF as first-line treatment of anovulatory infertility is not based on sound scientific evidence. It should be emphasized that PCOS represents a risk factor for developing ovarian hyperstimulation syndrome following ovarian hyperstimulation. In addition, healthy live birth rates from conventional ovulation induction strategies are good, with an acceptable rate of multiple pregnancies and ovarian hyperstimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newly introduced compounds to the field of ovulation induction such as insulin sensitizers and aromatase inhibitors may further improve outcomes. Furthermore, if ovarian responsiveness to ovulation-induction therapy could be predicted for an individual woman, it might be possible to devise regimens that reduce the risk of ovarian hyperstimulation and multiple pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/10/13482/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"       \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovulatory disorders are a common cause of infertility, which in most cases is treatable with ovulation induction agents. The goal of therapy in these women is monofollicular development and subsequent ovulation. This approach should be differentiated from stimulation of multiple follicle development in ovulatory women, as is done with assisted conception techniques.",
"   </p>",
"   <p>",
"    The method of ovulation induction selected by the clinician should be based upon the underlying cause of anovulation and the efficacy, costs, risks, and potential complications associated with each method as they apply to the individual woman.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with hypogonadotropic amenorrhea (WHO class 1), we recommend pulsatile GnRH as first-line therapy in countries where it is available. Because",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate is easy to administer, it is reasonable to give one course of clomiphene prior to initiating pulsatile GnRH. However, very few women in this group respond. If pulsatile GnRH is unavailable, gonadotropin therapy should be initiated, with both LH and FSH (these women do not respond to FSH alone). Both low-dose step-up and step-down protocols are reasonable.",
"      <br/>",
"      <br/>",
"      To minimize the risk of multiple gestation and ovarian hyperstimulation syndrome, gonadotropin cycles should be stopped if there are an excess number of follicles or extremely high serum estradiol concentrations.",
"     </li>",
"     <li>",
"      For women with WHO class 2 anovulation (most of whom have PCOS),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate is the first line infertility treatment. Doses, regimens, and monitoring are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"       \"Ovulation induction with clomiphene citrate\"",
"      </a>",
"      .) The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      may be useful in women who do not respond to clomiphene alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"       \"Metformin for treatment of the polycystic ovary syndrome\"",
"      </a>",
"      .) Other strategies are available as well for clomiphene-resistant patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"       \"Strategies for improving the efficacy of clomiphene induction of ovulation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If none of the clomiphene strategies are successful, then gonadotropin therapy should be started (in this case, FSH alone is sufficient). Strict attention to follicle number is essential to avoid complications (multiple gestation and ovarian hyperstimulation).",
"     </li>",
"     <li>",
"      For women with WHO Class 3 anovulation (hypergonadotropic hypogonadism, ie, ovarian failure), no ovulation induction strategy has been shown to be effective. However, in vitro fertilization with donor oocytes has high success rates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"       \"Oocyte donation for assisted reproduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with hyperprolactinemic anovulation should be treated with dopamine agonists.",
"     </li>",
"     <li>",
"      While there has been concern about a possible increased risk of ovarian cancer with ovulation induction drugs, it appears that the risk may be due to the infertility diagnosis rather than the medications themselves. However, because one study suggested an increase after 12 cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate, women should not receive more than 12 cycles.",
"      <br/>",
"      <br/>",
"      There does not appear to be an increased risk of breast cancer with ovulation induction drugs.",
"     </li>",
"     <li>",
"      While aromatase inhibitors appear to be effective in some studies, their precise role for ovulation induction remains unclear. Thus, we currently do not recommend their routine use.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/1\">",
"      Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985; 291:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/2\">",
"      De Souza MJ, Miller BE, Loucks AB, et al. High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. J Clin Endocrinol Metab 1998; 83:4220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/3\">",
"      Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002; 57:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/4\">",
"      Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/5\">",
"      Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/6\">",
"      Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/7\">",
"      KISTNER RW, SMITH OW. Observations on the use of a non-steroidal estrogen antagonist: MER-25. Surg Forum 1960; 10:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/8\">",
"      B&uuml;tzow TL, Kettel LM, Yen SS. Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome. Fertil Steril 1995; 63:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/9\">",
"      Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action--a hypothesis revisited. Fertil Steril 1984; 42:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/10\">",
"      Messinis IE, Nillius SJ. Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet Gynecol Scand 1982; 61:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/11\">",
"      Boostanfar R, Jain JK, Mishell DR Jr, Paulson RJ. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril 2001; 75:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/12\">",
"      Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997; 3:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/13\">",
"      Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/14\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/15\">",
"      Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update 2004; 10:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/16\">",
"      Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/17\">",
"      White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996; 81:3821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/18\">",
"      Balen AH, Braat DD, West C, et al. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Hum Reprod 1994; 9:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/19\">",
"      Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995; 63:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/20\">",
"      Hedon B, Hugues JN, Emperaire JC, et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum Reprod 1998; 13:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/21\">",
"      van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC. Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 1995; 10:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/22\">",
"      Imani B, Eijkemans MJ, Faessen GH, et al. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 2002; 77:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/23\">",
"      Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000; :CD000087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/24\">",
"      Nugent D, Vandekerckhove P, Hughes E, et al. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000; :CD000410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/25\">",
"      Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001; :CD002121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/26\">",
"      European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001; 86:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/27\">",
"      Devroey P, Boostanfar R, Koper NP, et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/28\">",
"      Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003; 79:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/29\">",
"      Buvat J, Buvat-Herbaut M, Marcolin G, et al. Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil Steril 1989; 52:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/30\">",
"      Shoham Z, Patel A, Jacobs HS. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 1991; 55:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/31\">",
"      Calaf Alsina J, Ruiz Balda JA, Romeu Sarri&oacute; A, et al. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG 2003; 110:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/32\">",
"      van Santbrink EJ, Fauser BC. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 1997; 82:3597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/33\">",
"      Balasch J, F&aacute;bregues F, Creus M, et al. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum Reprod 2001; 16:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/34\">",
"      Christin-Maitre S, Hugues JN, Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 2003; 18:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/35\">",
"      Hugues JN, C&eacute;drin-Durnerin I, Avril C, et al. Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome. Hum Reprod 1996; 11:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/36\">",
"      Eijkemans MJ, Imani B, Mulders AG, et al. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003; 18:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/37\">",
"      Mulders AG, Eijkemans MJ, Imani B, Fauser BC. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod Biomed Online 2003; 7:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/38\">",
"      Mulders AG, Laven JS, Imani B, et al. IVF outcome in anovulatory infertility (WHO group 2)--including polycystic ovary syndrome--following previous unsuccessful ovulation induction. Reprod Biomed Online 2003; 7:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/39\">",
"      Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005; 365:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/40\">",
"      Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/41\">",
"      Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/42\">",
"      Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/43\">",
"      Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996; 66:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/44\">",
"      Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/45\">",
"      Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/46\">",
"      Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009; 169:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/47\">",
"      Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/48\">",
"      Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/49\">",
"      Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/50\">",
"      Rodriguez C, Tatham LM, Calle EE, et al. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 1998; 9:645.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Management of infertility caused by ovulatory dysfunction. ACOG practice bulletin #34. American College of Obstetricians and Gynecologists, Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/52\">",
"      Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/53\">",
"      Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004; 160:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/54\">",
"      Ricci E, Parazzini F, Negri E, et al. Fertility drugs and the risk of breast cancer. Hum Reprod 1999; 14:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/55\">",
"      Rossing MA, Daling JR, Weiss NS, et al. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996; 60:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/56\">",
"      Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/57\">",
"      Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004; 19:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/58\">",
"      Gauthier E, Paoletti X, Clavel-Chapelon F, E3N group. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod 2004; 19:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/59\">",
"      Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003; 79:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/60\">",
"      Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006; 166:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/61\">",
"      Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J Natl Cancer Inst 2012; 104:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/62\">",
"      Brinton LA, Kr&uuml;ger Kjaer S, Thomsen BL, et al. Childhood tumor risk after treatment with ovulation-stimulating drugs. Fertil Steril 2004; 81:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/63\">",
"      Althuis MD, Scoccia B, Lamb EJ, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005; 193:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/64\">",
"      Martin KA, Hall JE, Adams JM, Crowley WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1993; 77:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/65\">",
"      Jansen RP. Pulsatile intravenous gonadotrophin releasing hormone for ovulation induction: determinants of follicular and luteal phase responses. Hum Reprod 1993; 8 Suppl 2:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/66\">",
"      Martin K, Santoro N, Hall J, et al. Clinical review 15: Management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab 1990; 71:1081A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/67\">",
"      Filicori M, Flamigni C, Dellai P, et al. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994; 79:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/68\">",
"      Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 1986; 10:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/69\">",
"      Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/70\">",
"      De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/10/13482/abstract/71\">",
"      van Santbrink EJ, Eijkemans MJ, Laven JS, Fauser BC. Patient-tailored conventional ovulation induction algorithms in anovulatory infertility. Trends Endocrinol Metab 2005; 16:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7407 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13482=[""].join("\n");
var outline_f13_10_13482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF ANOVULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHO class 1: Hypogonadotropic hypogonadal anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WHO class 2: Normogonadotropic normoestrogenic anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WHO class 3: Hypergonadotropic hypoestrogenic anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperprolactinemic anovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANTIESTROGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clomiphene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Addition of metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GONADOTROPIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Step-up protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Step-down protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Multiple gestation and ovarian hyperstimulation syndrome (OHSS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adjuvant treatment with GnRH analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PULSATILE GnRH THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Indication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      DOPAMINE AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Indication and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      LAPAROSCOPIC OVARIAN DIATHERMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      PRIMARY OVARIAN INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7407|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/3/4158\" title=\"figure 1\">",
"      Follicle devel follicular phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/31/11775\" title=\"figure 2\">",
"      Live births after clomiphene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/55/39805\" title=\"figure 3\">",
"      FSH threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/18/32045\" title=\"figure 4\">",
"      Low dose step up gonadotropins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/26/3502\" title=\"figure 5\">",
"      Step down gonadotropins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/63/12286\" title=\"figure 6\">",
"      Pregnancy rate singleton",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/58/20398\" title=\"figure 7\">",
"      Continuous GnRH LH and FSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/2/28717\" title=\"figure 8\">",
"      Dopamine agonists in prolactinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/21/1371\" title=\"table 1\">",
"      Rotterdam consensus criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/47/44795\" title=\"table 2\">",
"      Major causes of primary ovarian insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/4/11339\" title=\"table 3\">",
"      Efficacy of Rx for anovulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35479?source=related_link\">",
"      Classification and treatment of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=related_link\">",
"      Evaluation of the menstrual cycle and timing of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=related_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41510?source=related_link\">",
"      Management of lactotroph adenoma (prolactinoma) during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=related_link\">",
"      Neonatal outcome, complications, and management of multiple births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=related_link\">",
"      Ovulation induction with aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16660?source=related_link\">",
"      Pathogenesis of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=related_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22647?source=related_link\">",
"      Prevention of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=related_link\">",
"      Strategies for improving the efficacy of clomiphene induction of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_10_13483="Recommendations routine TBNA";
var content_f13_10_13483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for the routine performance of TBNA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        All patients presenting with mediastinal or hilar adenopathy or both should have 22G and/or 19G TBNA performed as the initial procedure. These results should provide a diagnosis of both malignant and nonmalignant diseases, as well as help in the staging of lung cancers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with visible endobronchial disease, 22G TBNA should be performed in case of a necrotic or a hemorragic tumor, or in a patient with a bleeding diathesis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All patients with evidence of submucosal and peribronchial disease should have 22G needle cytology sampling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TBNA should be the initial diagnostic procedure in all patients with peripheral lesions which extrinsically compress the bronchus but do not invade the lumen.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Dasgupta A, Mehta AC, Clin Chest Med 1999; 20:39 and Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13483=[""].join("\n");
var outline_f13_10_13483=null;
var title_f13_10_13484="Pulmonary allograft rejection";
var content_f13_10_13484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification and grading of pulmonary allograft rejection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        A: Acute rejection*: characterized by perivascular and interstitial mononuclear cell infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 0: none",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 1: minimal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 2: mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 3: moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 4: severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        B: Airway inflammation (lymphocytic bronchiolitis)*: characterized by mononuclear cell infiltrates in the submucosa of bronchioles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 0: none",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 1R",
"        <sup>",
"         &bull;",
"        </sup>",
"        : low grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 2R",
"        <sup>",
"         &bull;",
"        </sup>",
"        : high grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade X: ungradeable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        C: Chronic airway rejection (obliterative bronchiolitis): manifest by fibrous scarring that is often dense and eosinophilic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0: absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1: present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        D: Chronic vascular rejection - accelerated graft vascular sclerosis: characterized by fibrointimal thickening of the pulmonary arteries and veins. These lesions are not seen on TBB as they affect larger blood vessels than those accessed with TBB.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TBB: transbronchial biopsy.",
"     <br/>",
"     * Acute vascular rejection (A1 to A4) and acute airway inflammation (B1 to B2R) can be seen independently or may both be present.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     \"R\" denotes revised grade to avoid confusion with 1996 scheme.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:1229. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13484=[""].join("\n");
var outline_f13_10_13484=null;
var title_f13_10_13485="Risk factors pathogens CAP";
var content_f13_10_13485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiologic conditions and/or risk factors related to specific pathogens in community-acquired pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Commonly encountered pathogen(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholism",
"      </td>",
"      <td>",
"       <em>",
"        Streptococcus pneumoniae",
"       </em>",
"       , oral anaerobes,",
"       <em>",
"        Klebsiella pneumoniae, Acinetobacter",
"       </em>",
"       species,",
"       <em>",
"        Mycobacterium tuberculosis",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       COPD and/or smoking",
"      </td>",
"      <td>",
"       <em>",
"        Haemophilus influenzae, Pseudomonas aeruginosa, Legionella",
"       </em>",
"       species,",
"       <em>",
"        S. pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aspiration",
"      </td>",
"      <td>",
"       Gram-negative enteric pathogens, oral anaerobes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lung abscess",
"      </td>",
"      <td>",
"       CA-MRSA, oral anaerobes, endemic fungal pneumonia,",
"       <em>",
"        M. tuberculosis",
"       </em>",
"       , atypical mycobacteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exposure to bat or bird droppings",
"      </td>",
"      <td>",
"       <em>",
"        Histoplasma capsulatum",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exposure to birds",
"      </td>",
"      <td>",
"       <em>",
"        Chlamydophila psittaci",
"       </em>",
"       (if poultry: avian influenza)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exposure to rabbits",
"      </td>",
"      <td>",
"       <em>",
"        Francisella tularensis",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Exposure to farm animals or parturient cats",
"      </td>",
"      <td>",
"       <em>",
"        Coxiella burnetti",
"       </em>",
"       (Q fever)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV infection (early)",
"      </td>",
"      <td>",
"       <em>",
"        S. pneumoniae, H. influenzae, M. tuberculosis",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV infection (late)",
"      </td>",
"      <td>",
"       The pathogens listed for early infection plus",
"       <em>",
"        Pneumocystis jirovecii, Cryptococcus, Histoplasma, Aspergillus",
"       </em>",
"       , atypical mycobacteria (especially",
"       <em>",
"        Mycobacterium kansasii",
"       </em>",
"       ),",
"       <em>",
"        P. aeruginosa, H. influenzae",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hotel or cruise ship stay in previous 2 weeks",
"      </td>",
"      <td>",
"       <em>",
"        Legionella",
"       </em>",
"       species",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Travel to or residence in southwestern United States",
"      </td>",
"      <td>",
"       <em>",
"        Coccidioides",
"       </em>",
"       species,",
"       <em>",
"        Hantavirus",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Travel to or residence in Southeast and East Asia",
"      </td>",
"      <td>",
"       <em>",
"        Burkholderia pseudomallei",
"       </em>",
"       , avian influenza, SARS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Influenza active in community",
"      </td>",
"      <td>",
"       Influenza,",
"       <em>",
"        S. pneumoniae, Staphylococcus aureus, H. influenzae",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cough &gt;2 weeks with whoop or posttussive vomiting",
"      </td>",
"      <td>",
"       <em>",
"        Bordetella pertussis",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Structural lung disease (eg, bronchiectasis)",
"      </td>",
"      <td>",
"       <em>",
"        Pseudomonas aeruginosa, Burkholderia cepacia, S. aureus",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Injection drug use",
"      </td>",
"      <td>",
"       <em>",
"        S. aureus, anaerobes, M. tuberculosis, S. pneumoniae",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endobronchial obstruction",
"      </td>",
"      <td>",
"       Anaerobes,",
"       <em>",
"        S. pneumoniae, H. influenzae, S. aureus",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In context of bioterrorism",
"      </td>",
"      <td>",
"       <em>",
"        Bacillus anthracis",
"       </em>",
"       (anthrax),",
"       <em>",
"        Yersinia pestis",
"       </em>",
"       (plague),",
"       <em>",
"        Francisella tularensis",
"       </em>",
"       (tularemia)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CA-MRSA: community-acquired methicillin-resistant",
"     <em>",
"      Staphylococcus aureus",
"     </em>",
"     ; COPD: chronic obstructive pulmonary disease; SARS: severe acute respiratory syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mandell, LA, Wunderink, RG, Anzueto, A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27. Copyright &copy;2007 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13485=[""].join("\n");
var outline_f13_10_13485=null;
var title_f13_10_13486="Metyrapone in hypopituitarism";
var content_f13_10_13486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subnormal response to metyrapone in hypopituitarism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 446px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serum concentrations of 11-deoxycortisol (11-DOC) after the administration of metyrapone (750 mg every four hours for six doses) in normal subjects and patients with hypopituitarism. The serum 11-DOC concentrations are much lower in the patients with hypopituitarism due to the inability to substantially increase the secretion of ACTH. To convert serum II-deoxycortisol values to nmol/L multiply by 28.9.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Spark RF. Simplified assessment of pituitary-adrenal reserve. Measurement of serum 11-deoxycortisol and cortisol after metyrapone. Ann Intern Med 1971; 75:717.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13486=[""].join("\n");
var outline_f13_10_13486=null;
var title_f13_10_13487="Evaluation of congenital microcephaly";
var content_f13_10_13487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Evaluation of congenital microcephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Practice Committee of the Child Neurology Society. Practice parameter: Evaluation of the child with microcephaly (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2009; 73:887. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_10_13487=[""].join("\n");
var outline_f13_10_13487=null;
